

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy without rituximab in patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Lancet Oncology, The  
7, 379-391

DOI: [10.1016/s1470-2045\(06\)70664-7](https://doi.org/10.1016/s1470-2045(06)70664-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Anticorps monoclonal anti-CD20 (rituximab) dans les maladies h�matologiques et affections auto-immunes. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2006, 15, 270-277.	0.1	3
2	What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?. Leukemia and Lymphoma, 2006, 47, 2437-2439.	0.6	2
3	DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leukemia and Lymphoma, 2006, 47, 2558-2566.	0.6	33
4	Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Review of Anticancer Therapy, 2006, 6, 1175-1186.	1.1	35
5	New Drugs for the Treatment of Advanced-Stage Diffuse Large Cell Lymphomas. Seminars in Hematology, 2006, 43, 251-261.	1.8	11
6	Dose-Intensified Treatment of Advanced-Stage Diffuse Large B-Cell Lymphomas. Seminars in Hematology, 2006, 43, 221-229.	1.8	14
7	Standard Treatment of Advanced-Stage Diffuse Large B-Cell Lymphoma. Seminars in Hematology, 2006, 43, 213-220.	1.8	23
8	Role of Hematopoietic Stem Cell Transplantation for Advanced-Stage Diffuse Large Cell B-Cell Lymphoma-B. Seminars in Hematology, 2006, 43, 240-250.	1.8	15
9	Rituximab for early-stage diffuse large-B-cell lymphoma. Lancet Oncology, The, 2006, 7, 357-359.	5.1	21
10	Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncology, The, 2006, 7, 693-694.	5.1	104
12	Bcl-6, a Prognostic Biomarker in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma and Myeloma, 2006, 7, 104-105.	1.4	0
13	Bcl-2 Gene Expression as a Predictor of Outcome in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma and Myeloma, 2006, 6, 455-457.	1.4	34
14	Treatment of Non-Hodgkin's Lymphoma: A Look over the Past Decade. Clinical Lymphoma and Myeloma, 2006, 7, S7-S13.	1.4	30
15	Treatment of Diffuse Large B-Cell Lymphoma: A Risk-Based Approach. Clinical Lymphoma and Myeloma, 2006, 7, S14-S19.	1.4	4
17	Any drug that works has a target. Targeted Oncology, 2006, 1, 179-180.	1.7	0
18	The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Current Hematologic Malignancy Reports, 2006, 1, 220-229.	1.2	2
19	A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer, 2006, 107, 2826-2832.	2.0	44
21	Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma. Hematology American Society of Hematology Education Program, 2006, 2006, 295-302.	0.9	40

#	ARTICLE	IF	CITATIONS
24	Haematology. Journal of the Royal Army Medical Corps, 2006, 152, 250-265.	0.8	0
25	Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies. Current Topics in Medicinal Chemistry, 2006, 6, 1657-1686.	1.0	12
26	Disseminated Intravascular Bâ€Cell Lymphoma: Clinicopathological Features and Outcome of Three Cases Treated with Anthracyclineâ€Based Immunochemotherapy. Oncologist, 2006, 11, 923-928.	1.9	41
27	Primary gastrointestinal tract lymphoma: diagnosis and management of common neoplasms. Expert Review of Anticancer Therapy, 2006, 6, 1609-1628.	1.1	20
28	Newly diagnosed large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2007, 18, ii55-ii56.	0.6	2
29	Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Expert Review of Anticancer Therapy, 2007, 7, 257-273.	1.1	24
30	Primary Small-bowel Non-Hodgkin's Lymphoma: A Study of Clinical Features, Pathology, Management and Prognosis. Journal of International Medical Research, 2007, 35, 406-415.	0.4	43
31	Antibody Therapy in Aggressive Lymphomas. Hematology American Society of Hematology Education Program, 2007, 2007, 257-264.	0.9	5
32	The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. Expert Opinion on Biological Therapy, 2007, 7, 1749-1762.	1.4	8
33	Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: Newer therapies needed. Leukemia and Lymphoma, 2007, 48, 657-658.	0.6	0
34	Rituximab and Escalated Chemotherapy in Elderly Patients with Aggressive Diffuse Large-Cell Lymphoma: A Controlled Clinical Trial. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 194-199.	0.7	14
35	Phase I to III Trials of Antiâ€B Cell Therapy in Nonâ€Hodgkin's Lymphoma. Clinical Cancer Research, 2007, 13, 5636s-5642s.	3.2	13
36	Role of antibody therapy in lymphoid malignancies. British Medical Bulletin, 2007, 83, 275-290.	2.7	7
37	Role of Radiation Therapy in Localized Aggressive Lymphoma. Journal of Clinical Oncology, 2007, 25, 757-759.	0.8	21
38	Defucosylated Antiâ€CC Chemokine Receptor 4 Monoclonal Antibody Combined with Immunomodulatory Cytokines: A Novel Immunotherapy for Aggressive/Refractory Mycosis Fungoides and SÃ©zary Syndrome. Clinical Cancer Research, 2007, 13, 6494-6500.	3.2	58
39	Early Response Assessment Using 3â€Deoxy-3â€-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma. Clinical Cancer Research, 2007, 13, 3552-3558.	3.2	151
40	The clinical use of antibodies in haematological malignancies. Annals of Oncology, 2007, 18, ix51-ix57.	0.6	8
41	Sixth Biannual Report of the Cochrane Haematological Malignancies Group Focus on Non-Hodgkin Lymphoma. Journal of the National Cancer Institute, 2007, 99, E1-E1.	3.0	5

#	ARTICLE	IF	CITATIONS
42	Role of Chemotherapy and Rituximab for Treatment of Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1648-1659.	0.9	45
43	FCÂRIIIA and FCÂRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2007, 92, 998-999.	1.7	57
44	Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). <i>Blood</i> , 2007, 109, 2759-2766.	0.6	38
45	BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?. <i>Blood</i> , 2007, 109, 843-844.	0.6	10
46	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2007, 109, 1857-1861.	0.6	1,193
47	Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. <i>Blood</i> , 2007, 109, 4930-4935.	0.6	260
48	How I treat patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2007, 110, 29-36.	0.6	133
49	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2007, 110, 4396-4405.	0.6	103
51	Allogeneic transplantation in lymphoma: current status. <i>Haematologica</i> , 2007, 92, 1533-1548.	1.7	48
52	HIV-associated lymphoma: the evidence for treating aggressively but with caution. <i>Current Opinion in Oncology</i> , 2007, 19, 458-463.	1.1	19
53	CEOP-21 Versus CEOP-14 Chemotherapy With or Without Rituximab for the First-Line Treatment of Patients With Aggressive Lymphomas: Results of the HE22A99 Trial of the Hellenic Cooperative Oncology Group. <i>Cancer Journal (Sudbury, Mass )</i> , 2007, 13, 327-334.	1.0	15
54	New Treatment Concepts In Diffuse Large B-Cell Lymphomas (DLBL): Chemotherapy and Biological Therapy. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 149-162.	0.4	5
56	<i>REVIEW</i>. <i>Progress in Palliative Care</i> , 2007, 15, 225-232.	0.7	1
57	Lymphomas. <i>Update on Cancer Therapeutics</i> , 2007, 2, 101-110.	0.9	1
58	Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario. <i>Cancer Treatment Reviews</i> , 2007, 33, 161-176.	3.4	60
59	Autologous Stem Cell Transplantation in Lymphoma. <i>Seminars in Hematology</i> , 2007, 44, 234-245.	1.8	25
61	From: 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006, Orlando, FL. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 338-344.	1.4	0
62	From: 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL, June 1-5, 2007. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 452-461.	1.4	0

#	ARTICLE	IF	CITATIONS
63	The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era. <i>Leukemia and Lymphoma</i> , 2007, 48, 2121-2136.	0.6	28
64	High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. <i>Cancer and Leukemia Group B 9351. Leukemia and Lymphoma</i> , 2007, 48, 870-880.	0.6	5
65	Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: A large multicenter comparative study in patients with malignant lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 897-904.	0.6	13
66	Community-Based Trial of R-CHOP and Maintenance Rituximab for Intermediate- or High-Grade Non-Hodgkin Lymphoma with First-Cycle Filgrastim for Older Patients. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 354-360.	1.4	18
67	Aspects of Chemotherapy Schedules in Young and Elderly Patients with Aggressive Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 8, S43-S49.	1.4	5
68	Strategies for Improving Outcomes with 14-Day Anthracycline- Based Regimens in Patients with Aggressive Lymphomas. <i>Clinical Lymphoma and Myeloma</i> , 2007, 8, S50-S56.	1.4	1
70	Prolonged survival of an HIV-infected patient with plasmablastic lymphoma of the oral cavity. <i>American Journal of Hematology</i> , 2007, 82, 761-765.	2.0	28
71	Infectious complications of monoclonal antibodies used in cancer therapy. <i>Cancer</i> , 2007, 109, 2182-2189.	2.0	86
72	Study of radiolabeled indium <sup>111</sup> and yttrium <sup>90</sup> ibritumomab tiuxetan in primary central nervous system lymphoma. <i>Cancer</i> , 2007, 110, 2528-2534.	2.0	49
73	Rituximab therapy in malignant lymphoma. <i>Oncogene</i> , 2007, 26, 3603-3613.	2.6	203
74	Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab. <i>Oncogene</i> , 2007, 26, 3614-3628.	2.6	90
75	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). <i>Leukemia</i> , 2007, 21, 1802-1811.	3.3	66
76	Palliative care in haematology. <i>Internal Medicine Journal</i> , 2007, 37, 589-590.	0.5	19
77	Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Cancer Science</i> , 2008, 99, 179-184.	1.7	36
78	Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2007, 79, 100-106.	1.1	12
79	GEMOX regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. <i>European Journal of Haematology</i> , 2008, 80, 127-132.	1.1	90
80	Diffuse Large B-Cell Lymphoma. <i>Seminars in Radiation Oncology</i> , 2007, 17, 169-175.	1.0	33
81	Radioimmunotherapy as a Therapeutic Option for Non-Hodgkin's Lymphoma. <i>Seminars in Radiation Oncology</i> , 2007, 17, 176-183.	1.0	24

#	ARTICLE	IF	CITATIONS
82	T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature. <i>Leukemia and Lymphoma</i> , 2007, 48, 1764-1773.	0.6	57
83	Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy. <i>International Journal of Hematology</i> , 2007, 86, 49-57.	0.7	43
85	Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. <i>Annals of Hematology</i> , 2007, 86, 599-607.	0.8	122
86	Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. <i>Annals of Hematology</i> , 2007, 86, 639-645.	0.8	15
87	Proteasome inhibitor, bortezomib, for myeloma and lymphoma. <i>International Journal of Clinical Oncology</i> , 2007, 12, 318-326.	1.0	42
89	Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. <i>Supportive Care in Cancer</i> , 2007, 15, 877-884.	1.0	33
90	Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 235-241.	1.2	5
91	Pediatric non-Hodgkin's lymphoma. <i>Current Oncology Reports</i> , 2007, 9, 459-465.	1.8	38
92	Large gastrosplenic fistula after effective treatment of abdominal diffuse large-B-cell lymphoma. <i>Annals of Hematology</i> , 2008, 87, 337-338.	0.8	15
93	Influence of rituximab's CHOP therapy on clinical course and autoimmune parameters in rheumatoid arthritis associated with diffuse large B cell non-Hodgkin lymphoma. <i>Annals of Hematology</i> , 2008, 87, 767-769.	0.8	1
94	Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 785-790.	1.1	10
95	Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 299-304.	1.1	5
98	Observation of the curative effect of Mabthera in combination with the CHOP regimen in treating invasive B-cell lymphoma: A report of 45 cases. <i>Chinese Journal of Clinical Oncology</i> , 2008, 5, 215-218.	0.0	0
99	Pediatric non-Hodgkin lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 167-173.	1.2	13
100	Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 187-193.	1.2	7
101	Management of relapsed diffuse large B-cell lymphoma. <i>Current Oncology Reports</i> , 2008, 10, 393-403.	1.8	10
102	Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. <i>Current Oncology Reports</i> , 2008, 10, 420-426.	1.8	2
103	Rituximab in the treatment of primary bilateral adrenal lymphoma with adrenal crisis. <i>Medical Oncology</i> , 2008, 25, 107-109.	1.2	8

#	ARTICLE	IF	CITATIONS
104	Primary non-Hodgkin's lymphoma of the breast: eight-year follow-up experience. <i>International Journal of Hematology</i> , 2008, 87, 491-497.	0.7	42
105	The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 381-387.	1.2	33
106	Spontaneous regression of an EBV-associated monoclonal large B cell proliferation in the mastoid of a young child following surgical biopsy. <i>Pediatric Blood and Cancer</i> , 2008, 51, 557-559.	0.8	11
107	Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2008, 113, 2496-2503.	2.0	66
108	R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. <i>Hematological Oncology</i> , 2008, 26, 27-32.	0.8	15
109	Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study. <i>Hematological Oncology</i> , 2008, 26, 82-90.	0.8	10
110	Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication. <i>Hematological Oncology</i> , 2008, 26, 139-147.	0.8	6
111	MACOP-B and Involved-Field Radiotherapy Is an Effective and Safe Therapy for Primary Mediastinal Large B Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1154-1160.	0.4	40
112	Outcomes and Effect of Radiotherapy in Patients With Stage I or II Diffuse Large B-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1465-1471.	0.4	47
113	Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2008, 359, 613-626.	13.9	412
114	Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). <i>Leukemia</i> , 2008, 22, 2226-2229.	3.3	169
115	Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2008, 42, 93-98.	1.3	13
116	British HIV Association guidelines for HIV-associated malignancies 2008. <i>HIV Medicine</i> , 2008, 9, 336-388.	1.0	158
117	Decreasing mortality from non-Hodgkin lymphoma in Australia. <i>Internal Medicine Journal</i> , 2008, 38, 921-924.	0.5	6
118	Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. <i>British Journal of Haematology</i> , 2008, 140, 411-419.	1.2	107
119	Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. <i>British Journal of Haematology</i> , 2008, 142, 329-347.	1.2	90
120	Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profiling. <i>British Journal of Haematology</i> , 2008, 142, 166-178.	1.2	13
121	Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2008, 143, 268-273.	1.2	20

#	ARTICLE	IF	CITATIONS
122	Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma. <i>British Journal of Haematology</i> , 2008, 143, 672-680.	1.2	10
123	Newer monoclonal antibodies for hematological malignancies. <i>Experimental Hematology</i> , 2008, 36, 755-768.	0.2	75
124	Three cases of <i>Pneumocystis jirovecii</i> pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2008, 80, 275-276.	1.1	40
125	Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. <i>European Journal of Haematology</i> , 2008, 81, 448-453.	1.1	99
126	Cost-Effectiveness Analysis of the Addition of Rituximab to CHOP in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma. <i>Clinical Drug Investigation</i> , 2008, 28, 55-65.	1.1	29
127	The Importance of Cost Inputs and Sensitivity Analyses in a Cost-Effectiveness Analysis. <i>Clinical Drug Investigation</i> , 2008, 28, 461-462.	1.1	1
128	The Authors' Reply. <i>Clinical Drug Investigation</i> , 2008, 28, 462-463.	1.1	0
129	Extensive-Stage Small-Cell Lung Cancer: Evolution of Systemic Therapy and Future Directions. <i>Clinical Lung Cancer</i> , 2008, 9, 262-270.	1.1	15
130	Recent prognostic factors in diffuse large B-cell lymphoma indicate NF- $\kappa$ B pathway as a target for new therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2008, 49, 2048-2058.	0.6	29
131	Dose-intensified treatment of diffuse large B-cell lymphomas. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 24-30.	2.2	1
132	Managing the myelotoxicity of CHOP chemotherapy. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 31-36.	2.2	1
133	Management of gastric lymphoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2008, 6, 262-265.	0.8	4
134	Monoclonal antibodies in the treatment of lymphoid malignancies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 108, 267-271.	1.2	8
136	Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 259-267.	2.0	44
137	Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study. <i>Clinical Therapeutics</i> , 2008, 30, 1806-1816.	1.1	28
138	<i>Pneumocystis jirovecii</i> Pneumonia in Patients with Non-Hodgkin's Lymphoma Receiving Chemotherapy Containing Rituximab. <i>Journal of the Chinese Medical Association</i> , 2008, 71, 579-582.	0.6	19
139	Chemotherapy Combinations With Monoclonal Antibodies in Non-Hodgkin's Lymphoma. <i>Seminars in Hematology</i> , 2008, 45, 90-94.	1.8	32
140	Approved monoclonal antibodies for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1151-1158.	1.4	65



#	ARTICLE	IF	CITATIONS
141	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). <i>Lancet Oncology</i> , The, 2008, 9, 105-116.	5.1	1,001
142	Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. <i>Lancet Oncology</i> , The, 2008, 9, 435-444.	5.1	190
143	Adverse prognosis of bulky disease in good-risk DLBCL. <i>Lancet Oncology</i> , The, 2008, 9, 406-407.	5.1	2
144	Prognostic Systems for Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 839-861.	0.9	12
145	Diffuse Large B-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 941-952.	0.9	340
146	Overview of Lymphoma Diagnosis and Management. <i>Radiologic Clinics of North America</i> , 2008, 46, 175-198.	0.9	116
147	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). <i>Blood</i> , 2008, 112, 2248-2260.	0.6	199
148	Oncologic, Endocrine & Metabolic Emerging drugs in B-cell non-Hodgkin's lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 323-343.	1.0	1
149	Primary lymphoma of bone: an institutional experience. <i>Leukemia and Lymphoma</i> , 2008, 49, 2125-2132.	0.6	38
150	Pharmacotherapy of large B-cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2247-2258.	0.9	8
151	Non-Hodgkin lymphoma of the Waldeyer's ring: clinicopathologic and therapeutic issues. <i>Leukemia and Lymphoma</i> , 2008, 49, 2263-2271.	0.6	34
152	Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1651-1658.	1.1	29
153	Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group. <i>Leukemia and Lymphoma</i> , 2008, 49, 1074-1080.	0.6	50
154	PET Imaging for Response Assessment in Lymphoma: Potential and Limitations. <i>Radiologic Clinics of North America</i> , 2008, 46, 225-241.	0.9	39
155	Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). <i>Annals of Oncology</i> , 2008, 19, 545-552.	0.6	44
156	CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2008, 14, 2775-2784.	3.2	491
157	Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innovative nei Linfomi Survey. <i>Journal of Clinical Oncology</i> , 2008, 26, 3166-3175.	0.8	68
158	Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan. <i>Journal of Clinical Oncology</i> , 2008, 26, 3189-3195.	0.8	250

#	ARTICLE	IF	CITATIONS
159	Who should receive myeloablative therapy for diffuse large B-cell lymphoma?. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 442-443.	4.3	0
160	Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy. <i>Hematology</i> , 2008, 13, 261-266.	0.7	26
161	R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. <i>Haematologica</i> , 2008, 93, 1829-1836.	1.7	158
162	Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014. <i>Journal of Clinical Oncology</i> , 2008, 26, 2258-2263.	0.8	247
163	Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. <i>Journal of Clinical Oncology</i> , 2008, 26, 2717-2724.	0.8	267
164	Primary Mediastinal B-Cell Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 349-358.	0.9	65
165	A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma. <i>Annual Review of Medicine</i> , 2008, 59, 237-250.	5.0	174
166	Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 677-681.	4.3	1
167	Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1745-1751.	0.6	96
168	Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. <i>Acta Oncologica</i> , 2008, 47, 1029-1036.	0.8	38
169	Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 90-95.	0.8	150
170	Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. <i>Annals of Oncology</i> , 2008, 19, 560-565.	0.6	7
171	Recent therapeutic advances in hematological malignancies: the role of targeted therapies in lymphoma. <i>Annals of Oncology</i> , 2008, 19, v63-v67.	0.6	5
172	CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. <i>Annals of Oncology</i> , 2008, 19, 1921-1926.	0.6	82
173	Primary Adrenal Lymphoma Presenting with Cauda Equina Syndrome. <i>Scottish Medical Journal</i> , 2008, 53, 1-6.	0.7	1
174	Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , 2008, 19, 233-241.	0.6	203
175	Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. <i>Annals of Oncology</i> , 2008, 19, 538-544.	0.6	17
176	Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii67-ii69.	0.6	15

#	ARTICLE	IF	CITATIONS
177	Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century. <i>Archives of Internal Medicine</i> , 2008, 168, 469.	4.3	78
178	Current treatment approaches for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 663-676.	0.6	20
179	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 447-454.	0.8	159
180	What Constitutes "Improved Prognosis"? <i>Journal of Clinical Oncology</i> , 2008, 26, 1913-1914.	0.8	1
181	The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. <i>Annals of Oncology</i> , 2008, 19, 553-559.	0.6	21
183	Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1778-1783.	0.6	60
184	Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. <i>Leukemia and Lymphoma</i> , 2008, 49, 1345-1351.	0.6	23
186	Advances in tumour immunotherapy. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 675-683.	0.2	23
187	Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established. <i>Future Oncology</i> , 2008, 4, 199-210.	1.1	2
188	Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4587-4594.	0.8	287
189	Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1329-1336.	0.6	88
190	Chapter 6 Mechanisms Regulating the Susceptibility of Hematopoietic Malignancies to Glucocorticoid-Induced Apoptosis. <i>Advances in Cancer Research</i> , 2008, 101, 127-248.	1.9	67
191	Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: Analysis of remission induction and stem cell mobilization. <i>Leukemia and Lymphoma</i> , 2008, 49, 1337-1344.	0.6	8
192	Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. <i>Blood</i> , 2008, 111, 537-543.	0.6	142
193	Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. <i>Blood</i> , 2008, 112, 3312-3321.	0.6	81
194	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	0.6	173
195	Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. <i>Blood</i> , 2008, 112, 1374-1381.	0.6	112
198	Will targeted therapy hold its promise? An evidence-based review. <i>Current Opinion in Oncology</i> , 2008, 20, 104-111.	1.1	43

#	ARTICLE	IF	CITATIONS
199	The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. <i>Current Opinion in Pediatrics</i> , 2008, 20, 17-22.	1.0	38
200	Treatment of mucosa-associated lymphoid tissue-type ocular adnexal lymphoma. <i>Anti-Cancer Drugs</i> , 2008, 19, 673-680.	0.7	10
201	Antibodies and Hematologic Malignancies. <i>Cancer Journal (Sudbury, Mass )</i> , 2008, 14, 184-190.	1.0	3
202	The lymphomas and myeloma. , 0, , 347-369.		0
203	Pharmacokinetic Properties of Rituximab. <i>Reviews on Recent Clinical Trials</i> , 2008, 3, 22-30.	0.4	18
204	Rituximab in the treatment of non-Hodgkin's lymphoma. <i>Biologics: Targets and Therapy</i> , 2008, 2, 619.	3.0	24
205	Attenuated Antibody Reaction for the Primary Antigen but not for the Recall Antigen of Influenza Vaccination in Patients with Non-Hodgkin B-Cell Lymphoma after the Administration of Rituximab-CHOP. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2009, 49, 9-13.	0.3	46
206	Therapeutic decision making in BMT/SCT for non-Hodgkin lymphoma. , 0, , 99-126.		0
207	Expanded use of rituximab in the management of non-Hodgkin lymphoma. <i>OncoTargets and Therapy</i> , 2009, 2, 189.	1.0	4
209	Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP. <i>Leukemia and Lymphoma</i> , 2009, 50, 54-61.	0.6	20
210	Early detection of patients with poor risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1744-1747.	0.6	18
211	Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 357-363.	1.1	16
212	Defucosylated Anti-CCR4 Monoclonal Antibody Exerts Potent ADCC against Primary ATLL Cells Mediated by Autologous Human Immune Cells in NOD/Shi- <i>scid</i> , IL-2R <sup>3</sup> null Mice In Vivo. <i>Journal of Immunology</i> , 2009, 183, 4782-4791.	0.4	68
213	Rituximab and chemotherapy in diffuse large B-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 719-726.	1.1	11
214	Transplantation for non-Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 425-442.	1.0	8
215	Ten years of rituximab in NHL. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 223-235.	1.0	79
216	Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 99-104.	1.9	21
217	Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 491-500.	1.9	64

#	ARTICLE	IF	CITATIONS
218	Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5573-5579.	0.8	113
219	Why does cytotoxic chemotherapy cure only some cancers?. <i>Nature Clinical Practice Oncology</i> , 2009, 6, 43-52.	4.3	100
220	Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. <i>Annals of Oncology</i> , 2009, 20, 526-533.	0.6	55
223	Primary diffuse large B-cell lymphoma of the breast. <i>Archive of Oncology</i> , 2009, 17, 80-82.	0.2	1
224	Intravascular lymphomatosis of the brain in a patient with myelodysplastic syndrome. <i>Nature Reviews Neurology</i> , 2009, 5, 288-292.	4.9	4
225	Hodgkin's disease and non-Hodgkin's lymphoma. , 2009, , 97-104.		0
226	Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2009, 20, 1985-1992.	0.6	64
227	Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv110-iv112.	0.6	39
228	Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence. <i>Oncologist</i> , 2009, 14, 17-29.	1.9	35
229	Applications of monoclonal antibodies for the treatment of hematological malignancies. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 207-220.	1.4	15
230	Aggressive non-Hodgkin's lymphoma. <i>Medicine</i> , 2009, 37, 202-207.	0.2	1
231	Rapid infusion of rituximab over 60 min. <i>European Journal of Haematology</i> , 2009, 82, 322-325.	1.1	40
232	Immunotherapy of cancer. <i>European Journal of Pharmacology</i> , 2009, 625, 41-54.	1.7	85
233	The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2010, 28, 27-32.	0.8	31
234	Expression of the ULBP ligands for NKG2D by NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. <i>International Journal of Cancer</i> , 2009, 125, 212-221.	2.3	31
235	A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. <i>Cancer</i> , 2009, 115, 4547-4553.	2.0	255
236	Diffuse large B-cell lymphoma. <i>Cancer</i> , 2009, 115, 4980-4989.	2.0	23
237	Anthracycline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 459-466.	1.2	0

#	ARTICLE	IF	CITATIONS
238	A case of non-Hodgkinâ€™s lymphoma primary arising in both adrenal glands associated with adrenal failure. <i>Endocrine</i> , 2009, 35, 34-37.	1.1	12
239	Diffuse Large B Cell Lymphoma of the Mesentery: An Unusual Presentation and Review of the Literature. <i>Journal of Gastrointestinal Cancer</i> , 2009, 40, 79-82.	0.6	15
240	Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. <i>Clinical and Translational Oncology</i> , 2009, 11, 604-608.	1.2	4
241	The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. <i>International Journal of Hematology</i> , 2009, 89, 326-331.	0.7	8
242	Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. <i>International Journal of Hematology</i> , 2009, 89, 577-583.	0.7	87
243	Clinical significance of co-expression of CD21 and LFA-1 in B-cell lymphoma. <i>International Journal of Hematology</i> , 2009, 89, 497-507.	0.7	4
244	Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition. <i>International Journal of Hematology</i> , 2009, 89, 600-610.	0.7	41
245	Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. <i>International Journal of Hematology</i> , 2009, 90, 74-80.	0.7	25
246	Beyond R-CHOP and the IPI in large-cell lymphoma: Molecular markers as an opportunity for stratification. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 218-224.	1.2	23
247	Treatment of diffuse large B-cell lymphomas. <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 150-153.	0.3	0
249	Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2R $\beta$ 3null mouse model. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1195-1206.	2.0	132
250	Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkinâ€™s lymphoma: results of a prospective randomized controlled trial. <i>Annals of Hematology</i> , 2009, 88, 51-57.	0.8	25
251	Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate. <i>Annals of Hematology</i> , 2009, 88, 433-439.	0.8	19
252	Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population. <i>Annals of Hematology</i> , 2009, 88, 863-869.	0.8	13
253	A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory Bâ€cell (CD20+) nonâ€Hodgkin lymphoma and mature Bâ€cell acute lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2009, 52, 177-181.	0.8	158
254	Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and nonâ€Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2009, 52, 664-666.	0.8	21
255	The combination of monoclonal antibodies and conventional chemotherapy for children with malignant lymphoma: Opportunities and challenges. <i>Pediatric Blood and Cancer</i> , 2009, 52, 150-152.	0.8	3
256	A case of natural killer cell lymphoma presenting with bilateral pleural effusions and hemophagocytic lymphohistocytosis. <i>Pediatric Blood and Cancer</i> , 2009, 52, 666-669.	0.8	7

#	ARTICLE	IF	CITATIONS
257	Limited Impact of the Thymus on Immunological Recovery During and After Chemotherapy in Patients with Diffuse Large B-cell Lymphoma. <i>Scandinavian Journal of Immunology</i> , 2009, 69, 547-554.	1.3	3
258	Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. <i>Cancer Science</i> , 2009, 100, 1842-1847.	1.7	88
259	Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. <i>British Journal of Haematology</i> , 2009, 144, 24-40.	1.2	106
260	Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INCA-EU Prospective Observational European Neutropenia Study. <i>British Journal of Haematology</i> , 2009, 144, 677-685.	1.2	89
261	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. <i>Leukemia</i> , 2009, 23, 1118-1126.	3.3	104
262	Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT. <i>Bone Marrow Transplantation</i> , 2009, 43, 323-325.	1.3	6
263	Recent developments in the treatment of aggressive non-Hodgkin lymphoma. <i>Blood Reviews</i> , 2009, 23, 11-23.	2.8	23
264	Pharmaceutical Perspectives of Cancer Therapeutics. , 2009, , .		15
265	Long-term survival expectations of cancer patients in Europe in 2000-2002. <i>European Journal of Cancer</i> , 2009, 45, 1028-1041.	1.3	87
267	Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1455-1464.	2.0	52
268	Intravascular large B-cell lymphoma: Remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 885-888.	0.6	9
270	Les lymphomes agressifs. <i>Medecine Nucleaire</i> , 2009, 33, 478-481.	0.2	3
271	Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?. <i>Leukemia and Lymphoma</i> , 2009, 50, 1992-1998.	0.6	8
272	CD43 Expression Is an Adverse Prognostic Factor in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 133-137.	1.4	21
273	The 45th Annual Meeting of the American Society of Clinical Oncology Orlando, FL; May 29 - June 2, 2009. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 345-352.	1.4	0
275	Protein kinase C-beta11 expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. <i>Leukemia and Lymphoma</i> , 2009, 50, 1666-1675.	0.6	20
276	Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 116.	3.5	55
277	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. <i>Blood</i> , 2009, 114, 3533-3537.	0.6	566

#	ARTICLE	IF	CITATIONS
278	Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. <i>Journal of Clinical Oncology</i> , 2009, 27, 605-611.	0.8	576
279	The late adverse events of rituximab therapy â€“ rare but there!. <i>Leukemia and Lymphoma</i> , 2009, 50, 1083-1095.	0.6	116
280	Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. <i>Leukemia and Lymphoma</i> , 2009, 50, 873-885.	0.6	49
281	Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomycin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0â€“1) diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1824-1829.	0.6	5
282	Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucemie (GIMURELL) study. <i>Leukemia and Lymphoma</i> , 2009, 50, 1475-1481.	0.6	1
283	Analisi di costo-efficacia di rituximab piÃ¹ CHOP versus ProMACE-CytaBOM nel trattamento del linfoma diffuso a grandi cellule B: lâ€™esperienza di Reggio Emilia. <i>Giornale Italiano Di Health Technology Assessment</i> , 2009, 2, 55-64.	0.1	0
284	Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. <i>Leukemia and Lymphoma</i> , 2009, 50, 179-186.	0.6	16
285	Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1818-1823.	0.6	52
286	[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2009, 50, 904-911.	0.6	16
287	Bendamustine: Rebirth of an Old Drug. <i>Journal of Clinical Oncology</i> , 2009, 27, 1492-1501.	0.8	237
288	Therapy of diffuse large B-cell lymphomas. <i>European Journal of Cancer</i> , 2009, 45, 386-387.	1.3	2
289	Rituximab Combined With MACOP-B or VACOP-B and Radiation Therapy in Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 381-385.	1.4	70
290	Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 949-971.	0.9	49
291	Localized large cell lymphoma: is there any need for radiation therapy?. <i>Current Opinion in Oncology</i> , 2009, 21, 401-406.	1.1	18
294	First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions. <i>Haematologica</i> , 2009, 94, 1194-1198.	1.7	7
295	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009, 94, 1250-1258.	1.7	65
296	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	0.6	829
297	Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. <i>Blood</i> , 2009, 113, 4885-4893.	0.6	217



#	ARTICLE	IF	CITATIONS
298	CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). <i>Blood</i> , 2009, 113, 3896-3902.	0.6	288
299	HIV-associated lymphomas and gamma-herpesviruses. <i>Blood</i> , 2009, 113, 1213-1224.	0.6	317
301	Targeted therapies in B-cell non-Hodgkin lymphomas. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 371-380.	0.2	1
302	Primary bone lymphoma of the mandible and thyroid incidentaloma identified by 18FDG PET/CT: a case report. <i>Cases Journal</i> , 2009, 2, 6384.	0.4	9
303	Front-line management of diffuse large B cell lymphoma. <i>Current Opinion in Oncology</i> , 2010, 22, 642-645.	1.1	27
304	Monoclonal Antibody Therapy in Haematological Malignancies. <i>Current Clinical Pharmacology</i> , 2010, 5, 148-159.	0.2	7
305	Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2010, 5, 197-204.	0.8	9
309	HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab-mediated lysis. <i>Haematologica</i> , 2010, 95, 2063-2071.	1.7	28
310	9. Current Treatment and Future Prospects of Malignant Lymphoma.. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2010, 99, 542-547.	0.0	0
311	2010, 99, 2159-2164.	0.0	0
312	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 288-334.	2.3	233
313	Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2010, 115, 3008-3016.	0.6	254
314	An Update on the Role of Interim Restaging FDG-PET in Patients With Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 347-352.	2.3	24
315	Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. <i>International Journal of Hematology</i> , 2010, 91, 258-266.	0.7	20
316	Profiling the Cancer Genome. <i>Annual Review of Genomics and Human Genetics</i> , 2010, 11, 133-159.	2.5	43
317	A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2R <sup>β</sup> null mouse lymphoma model. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1791-1800.	2.0	35
318	The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. <i>Annals of Hematology</i> , 2010, 89, 171-177.	0.8	26
319	Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2010, 89, 263-272.	0.8	16

#	ARTICLE	IF	CITATIONS
320	Dose-dense therapy improves survival in aggressive non-Hodgkinâ€™s lymphoma. <i>Annals of Hematology</i> , 2010, 89, 273-282.	0.8	6
321	Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. <i>Annals of Hematology</i> , 2010, 89, 283-289.	0.8	11
322	Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. <i>Annals of Hematology</i> , 2010, 89, 783-787.	0.8	21
323	Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 571-577.	1.1	15
324	Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 27-34.	1.0	43
325	Treatment of NonHodgkinâ€™s lymphomas with rituximab in Slovene patients. <i>Medical Oncology</i> , 2010, 27, 167-176.	1.2	2
326	SEOM clinical guidelines for the treatment of diffuse large B-cell lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 765-769.	1.2	1
327	Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkinâ€™s lymphoma: single center, 15-year experience. <i>International Journal of Hematology</i> , 2010, 91, 78-86.	0.7	18
328	Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. <i>International Journal of Hematology</i> , 2010, 91, 456-463.	0.7	22
329	Current treatment strategy of diffuse large B-cell lymphomas. <i>International Journal of Hematology</i> , 2010, 92, 231-237.	0.7	27
330	Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. <i>International Journal of Hematology</i> , 2010, 92, 732-743.	0.7	37
331	CHOP-like regimen in combination with rituximab and peginterferon alpha-2b in newly-diagnosed diffuse large B-cell Non-Hodgkinâ€™s lymphoma: Experience in a Chinese center. <i>Clinical Oncology and Cancer Research</i> , 2010, 7, 103-109.	0.1	0
332	Stem Cell Transplantation in Childhood Non-Hodgkinâ€™s Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 192-199.	1.2	5
333	Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 393-408.	157.7	143
334	Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia. <i>BMC Cancer</i> , 2010, 10, 231.	1.1	14
335	Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. <i>BMC Cancer</i> , 2010, 10, 321.	1.1	73
336	Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). <i>BMC Cancer</i> , 2010, 10, 625.	1.1	38
337	DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population. <i>Cancer Genetics and Cytogenetics</i> , 2010, 196, 31-37.	1.0	15

#	ARTICLE	IF	CITATIONS
338	Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2010, 198, 40-46.	1.0	41
339	B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. <i>Experimental Hematology</i> , 2010, 38, 213-221.	0.2	35
340	Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBeAb-positive: a multicenter retrospective study. <i>European Journal of Haematology</i> , 2010, 85, 243-250.	1.1	58
341	Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 5432-5439.	2.0	45
342	Multicentre phase II study of CycLOBEAP plus rituximab in patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2010, 28, 68-74.	0.8	11
343	VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: A multicenter experience. <i>Archives of Gerontology and Geriatrics</i> , 2010, 51, 209-215.	1.4	7
344	Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. <i>Leukemia Research</i> , 2010, 34, 1175-1179.	0.4	24
345	Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise. <i>Blood Reviews</i> , 2010, 24, 69-82.	2.8	13
346	Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 19-26.	1.0	15
347	Involved Field Radiation After Autologous Stem Cell Transplant for Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 79-85.	0.4	34
348	Involved-Lesion Radiation Therapy After Chemotherapy in Limited-Stage Head-and-Neck Diffuse Large B Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 507-512.	0.4	20
349	Targeted therapy in haematological malignancies. <i>Journal of Pathology</i> , 2010, 220, 404-418.	2.1	29
350	Phase I study of inotuzumab ozogamicin (CMC544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. <i>Cancer Science</i> , 2010, 101, 1840-1845.	1.7	55
351	Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. <i>Cancer Science</i> , 2010, 101, 2579-2585.	1.7	14
352	Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBe antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. <i>Journal of Viral Hepatitis</i> , 2010, 17, 807-815.	1.0	85
353	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). <i>British Journal of Haematology</i> , 2010, 148, 235-244.	1.2	38
354	Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. <i>British Journal of Haematology</i> , 2010, 149, 237-243.	1.2	15
355	High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>British Journal of Haematology</i> , 2010, 149, 560-568.	1.2	71

#	ARTICLE	IF	CITATIONS
356	Phase II trial of zanolimumab (HuMax $\alpha$ CD4) in relapsed or refractory non $\alpha$ cutaneous peripheral T cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 565-573.	1.2	73
357	Comparison of conventional prognostic indices in patients older than 60 $\alpha$ years with diffuse large B $\alpha$ cell lymphoma treated with R $\alpha$ CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 $\alpha$ years in an elderly prognostic index (E $\alpha$ PI). <i>British Journal of Haematology</i> , 2010, 151, 143-151.	1.2	85
358	Ocular adnexal diffuse large B-cell lymphoma: local disease correlates with better outcomes. <i>Eye</i> , 2010, 24, 954-961.	1.1	27
359	Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. <i>Bone Marrow Transplantation</i> , 2010, 45, 303-309.	1.3	3
360	Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness. <i>ClinicoEconomics and Outcomes Research</i> , 2010, 2, 37.	0.7	3
361	Survival from haematological malignancy in childhood, adolescence and young adulthood in Australia: is the age $\alpha$ related gap narrowing?. <i>Medical Journal of Australia</i> , 2010, 193, 217-221.	0.8	12
364	Rituximab purging and maintenance therapy combined with autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2010, 1, 733-738.	0.8	8
365	Current and future issue of molecular target therapy in hematological malignancy. <i>Drug Delivery System</i> , 2010, 25, 126-133.	0.0	0
366	Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. <i>The Korean Journal of Hematology</i> , 2010, 45, 253.	0.7	7
367	Utility of Influenza Vaccination for Oncology Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 2481-2490.	0.8	96
368	Small Intestinal Cancer: a Population-Based Study of Incidence and Survival Patterns in the United States, 1992 to 2006. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1908-1918.	1.1	75
369	HIV-related lymphoma. <i>HIV Therapy</i> , 2010, 4, 649-659.	0.6	7
370	Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 1046-1052.	0.6	182
371	How I treat elderly patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 116, 5103-5110.	0.6	124
372	High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis. <i>Annals of Oncology</i> , 2010, 21, 1064-1071.	0.6	14
373	Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 4170-4176.	0.8	223
374	Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 3998-4004.	3.2	60
375	Review of the Safety and Feasibility of Rapid Infusion of Rituximab. <i>Journal of Oncology Practice</i> , 2010, 6, 91-93.	2.5	27

#	ARTICLE	IF	CITATIONS
376	Rituximab Combined with Autologous Peripheral Blood Stem Cell Transplantation Improve Therapeutic Effects of Chemotherapy in Pediatric Patients with Burkitt's Lymphoma. <i>Journal of Tropical Pediatrics</i> , 2010, 56, 337-341.	0.7	3
377	Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1591-1598.	0.8	351
378	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 412-417.	0.8	75
379	Hepatitis B Reactivation and Rituximab in the Oncology Practice. <i>Oncologist</i> , 2010, 15, 1113-1121.	1.9	23
380	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. <i>Clinical Cancer Research</i> , 2010, 16, 2435-2442.	3.2	25
381	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience. <i>Acta Haematologica</i> , 2010, 123, 48-54.	0.7	15
382	Retroperitoneal Diffuse Large B-Cell Lymphoma Presenting As Pseudoachalasia. <i>Journal of Clinical Oncology</i> , 2010, 28, e184-e187.	0.8	11
383	High incidence of <i>Pneumocystis jirovecii</i> pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , 2010, 51, 797-801.	0.6	62
384	Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 4184-4190.	0.8	1,331
385	Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20 <sup>+</sup> B-Cell Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 2373-2380.	0.8	501
386	Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low to intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. <i>Leukemia and Lymphoma</i> , 2010, 51, 1668-1677.	0.6	2
387	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. <i>Blood</i> , 2010, 116, 2040-2045.	0.6	1,193
388	Investigational Immunotherapeutics for B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2010, 28, 884-892.	0.8	22
389	Novel disease targets and management approaches for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-10.	0.6	25
390	Unresolved issues in diffuse large B-cell lymphomas. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 387-402.	1.1	6
391	Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. <i>Annals of Oncology</i> , 2010, 21, 1486-1491.	0.6	79
392	Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v172-v174.	0.6	61
393	Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-14.	3.3	20

#	ARTICLE	IF	CITATIONS
394	High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2010, 21, 2255-2261.	0.6	30
395	Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies. <i>Current Drug Targets</i> , 2010, 11, 790-800.	1.0	10
396	Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma. <i>Clinical Cancer Research</i> , 2010, 16, 1520-1531.	3.2	222
397	High grade lymphoma: acute presentation and management. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2010, 71, 252-257.	0.2	0
398	Diversity in antibody-based approaches to non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 20-27.	0.6	15
399	Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2010, 51, 146-148.	0.6	9
400	Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. <i>Annals of Oncology</i> , 2010, 21, 1217-1221.	0.6	22
401	Prognostic impact of protein kinase C $\hat{I}^2$ II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. <i>Modern Pathology</i> , 2010, 23, 686-693.	2.9	20
402	Diagnostic Strategy for Hematology and Oncology Patients with Acute Respiratory Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1038-1046.	2.5	253
403	Primary bone lymphoma – the University of Miami experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 39-49.	0.6	66
406	Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. <i>Leukemia and Lymphoma</i> , 2010, 51, 422-429.	0.6	2
407	Anti-CD20 monoclonal antibodies: historical and future perspectives. <i>Haematologica</i> , 2010, 95, 135-143.	1.7	228
408	Rituximab. <i>Drugs</i> , 2010, 70, 1445-1476.	4.9	163
409	Rituximab for the Treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia. <i>Drugs</i> , 2010, 70, 261-272.	4.9	42
410	The 51st Annual Meeting of the American Society of Hematology. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 11-20.	0.2	1
411	Brief-Duration Rituximab/Chemotherapy Followed by Maintenance Rituximab in Patients With Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 44-50.	0.2	30
413	Prognostic Significance of BAD and AIF Apoptotic Pathways in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 118-124.	0.2	13
414	Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 192-196.	0.2	53

#	ARTICLE	IF	CITATIONS
415	A Decade of Progress in Lymphoma: Advances and Continuing Challenges. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 414-423.	0.2	43
416	Management of Rare Adult Tumours. , 2010, , .		2
417	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
418	Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3115-3121.	0.8	170
419	Immunohistochemical Profiling of Lymphoma. , 2010, , 21-44.		0
420	Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1353-1365.	1.1	8
421	CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. <i>Human Pathology</i> , 2010, 41, 271-280.	1.1	31
422	A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B-Cell Lymphoma: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 35-45.	2.0	88
424	CD20-Targeted Therapy: The Next Generation of Antibodies. <i>Seminars in Hematology</i> , 2010, 47, 199-210.	1.8	85
425	Rituximab in High-Grade Lymphoma. <i>Seminars in Hematology</i> , 2010, 47, 148-155.	1.8	17
426	New drugs for aggressive B-cell and T-cell lymphomas. <i>Lancet Oncology</i> , The, 2010, 11, 1074-1085.	5.1	53
427	Characterization of D-cyclin proteins in hematology neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. <i>Modern Pathology</i> , 2010, 23, 420-433.	2.9	39
428	Non-Hodgkin's Lymphoma in the Elderly. <i>Drugs and Aging</i> , 2010, 27, 211-238.	1.3	7
429	Clinicopathologic features and treatment options of ocular adnexal lymphoma. <i>Expert Review of Ophthalmology</i> , 2010, 5, 241-258.	0.3	0
430	Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2010, 51, 1225-1232.	0.6	36
431	Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. <i>Blood</i> , 2010, 116, 5119-5125.	0.6	123
432	Therapeutic options for HIV-associated lymphomas. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2471-2481.	0.9	6
433	Rituximab in hematopoietic cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 971-982.	1.4	5

#	ARTICLE	IF	CITATIONS
434	A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. <i>Acta Oncol</i> , 2010, 49, 3-12.	0.8	30
435	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. <i>Leukemia and Lymphoma</i> , 2010, 51, 199-212.	0.6	88
436	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011, 52, 823-832.	0.6	23
437	Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011, 52, 1239-1248.	0.6	15
438	Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma of the Elderly: What We Know So Far. <i>Oncologist</i> , 2011, 16, 87-96.	1.9	99
439	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.	0.8	190
440	Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 443-455.	1.1	3
441	Prognostication of diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2011, 52, 360-373.	0.6	28
442	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. <i>Leukemia and Lymphoma</i> , 2011, 52, 153-156.	0.6	6
443	Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. <i>Annals of Oncology</i> , 2011, 22, 664-670.	0.6	177
444	Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2097-2104.	0.6	9
445	Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 462-466.	0.2	106
446	Rituximab-induced Acute Eosinophilic Pneumonia with Diffuse Alveolar Damage: A Case Report. <i>Journal of Experimental and Clinical Medicine</i> , 2011, 3, 314-317.	0.2	3
447	Prognostic Relevance of Immunohistochemical Subclassification of Diffuse Large B-Cell Lymphoma in Two Prospective Phase III Clinical Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 23-32.	0.2	11
448	New antibody drug treatments for lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 623-640.	1.4	15
449	Cancer Immunotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 1-64.	0.7	120
450	A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. <i>Leukemia and Lymphoma</i> , 2011, 52, 587-596.	0.6	26
452	Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. <i>Annals of Oncology</i> , 2011, 22, 1382-1391.	0.6	26



#	ARTICLE	IF	CITATIONS
453	Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study. Journal of the Egyptian National Cancer Institute, 2011, 23, 17-24.	0.6	17
454	Changing therapeutic landscape – The last decade. Transfusion and Apheresis Science, 2011, 44, 155-159.	0.5	1
455	Improving therapy for patients with aggressive lymphoma. Transfusion and Apheresis Science, 2011, 44, 179-182.	0.5	0
456	Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncology, The, 2011, 12, 1258-1266.	5.1	91
457	CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncology, The, 2011, 12, 1013-1022.	5.1	633
458	Rituximab in DLBCL: 6 years on. Lancet Oncology, The, 2011, 12, 984-985.	5.1	4
459	Use of prechemotherapy positron emission tomography-CT imaging, acquired in the treatment position, to help plan involved nodal radiotherapy for a patient with diffuse large B-cell lymphoma. Journal of Medical Imaging and Radiation Oncology, 2011, 55, 236-241.	0.9	1
460	Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies. Community Oncology, 2011, 8, 311-325.	0.2	2
461	Adverse effects of biologics: a network meta-analysis and Cochrane overview. The Cochrane Library, 2016, 2016, CD008794.	1.5	481
462	The Evolving Role of Bendamustine in Lymphoid Malignancy: Understanding the Drug and Its Mechanism of Action – Introduction. Seminars in Hematology, 2011, 48, S1-S3.	1.8	4
463	Does rituximab increase the incidence of infectious complications? A narrative review. International Journal of Infectious Diseases, 2011, 15, e2-e16.	1.5	178
464	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNHO3-2B): an open-label randomised phase 3 trial. Lancet, The, 2011, 378, 1858-1867.	6.3	311
465	Intensified chemotherapy for diffuse large B-cell lymphomas. Lancet, The, 2011, 378, 1828-1829.	6.3	3
466	An odd cause of dysphagia. BMJ: British Medical Journal, 2011, 342, d737-d737.	2.4	0
467	Importance of Relative Dose Intensity in Chemotherapy for Diffuse Large B-Cell Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2011, 51, 1-5.	0.3	40
468	Case Studies of Elderly Patients with Non-Hodgkin's Lymphoma. Hematology Reports, 2011, 3, e7.	0.3	2
469	Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma. Hematology Reports, 2011, 3, e1.	0.3	1
470	Current approaches to the treatment of non-Hodgkin's lymphoma. Hematology Reports, 2011, 3, e3.	0.3	2

#	ARTICLE	IF	CITATIONS
471	Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma. <i>The Korean Journal of Hematology</i> , 2011, 46, 103.	0.7	12
473	Rituximab in treatment of post-transplant lymphoproliferative disease after allogeneic stem cell transplantation. <i>Wspolczesna Onkologia</i> , 2011, 3, 155-158.	0.7	1
474	Recurrent PET FDG Uptake after Sequential Chemotherapy and Radiation Therapy for DLBCL of the Tibia: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2011, 2011, 1-6.	0.2	1
475	Clinical Trial Risk in Non-Hodgkin's Lymphoma: Endpoint and Target Selection. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2011, 14, 227.	0.9	18
476	Epstein-Barr Virus-Induced Gene 3 (EBI3): A Novel Diagnosis Marker in Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2011, 6, e24617.	1.1	26
477	Hematopoietic Cell Transplantation for Lymphomas. <i>Cancer Control</i> , 2011, 18, 246-257.	0.7	17
478	Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab?. <i>Proceedings of Singapore Healthcare</i> , 2011, 20, 48-54.	0.2	1
480	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 117, 2405-2413.	0.6	30
481	miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. <i>Blood</i> , 2011, 118, 1034-1040.	0.6	90
482	Malignant hematologic diseases in adolescents and young adults. <i>Blood</i> , 2011, 117, 5803-5815.	0.6	99
483	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Blood</i> , 2011, 117, 4836-4843.	0.6	280
484	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	0.6	168
485	Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. <i>Blood</i> , 2011, 118, 4808-4816.	0.6	81
486	Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. <i>International Journal of Oncology</i> , 2011, 39, 1413-20.	1.4	20
487	Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma. <i>Oncology Reports</i> , 2011, 25, 1183-90.	1.2	17
488	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. <i>Haematologica</i> , 2011, 96, 1136-1143.	1.7	84
490	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 484-560.	2.3	161
491	New therapeutic targets and drugs in non-Hodgkin's lymphoma. <i>Current Opinion in Hematology</i> , 2011, 18, 1.	1.2	17

#	ARTICLE	IF	CITATIONS
492	Immunopathogenesis of lymphoma: Focus on CCR4. <i>Cancer Science</i> , 2011, 102, 44-50.	1.7	60
493	Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. <i>Cancer Science</i> , 2011, 102, 1687-1692.	1.7	25
494	Rituximab in combination with CODOX/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. <i>British Journal of Haematology</i> , 2011, 152, 175-181.	1.2	29
495	Multikinase inhibitor sorafenib exerts cytotoxic efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. <i>British Journal of Haematology</i> , 2011, 152, 401-412.	1.2	15
496	Distinct cellular and therapeutic effects of obatoclox in rituximab-sensitive and -resistant lymphomas. <i>British Journal of Haematology</i> , 2011, 153, 599-611.	1.2	50
497	Radioimmunotherapy with <sup>131</sup> I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 136-145.	0.7	22
498	Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 346-350.	0.7	6
499	Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*. <i>European Journal of Haematology</i> , 2011, 86, 124-128.	1.1	80
500	Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2011, 86, 117-123.	1.1	7
501	The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas. <i>European Journal of Haematology</i> , 2011, 86, 466-476.	1.1	5
502	Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. <i>European Journal of Haematology</i> , 2011, 87, 217-227.	1.1	27
503	Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. <i>European Journal of Haematology</i> , 2011, 87, 434-440.	1.1	29
504	Antibodies in oncology. <i>New Biotechnology</i> , 2011, 28, 518-529.	2.4	62
505	Personalized Treatment of Lymphoma: Promise and Reality. <i>Seminars in Oncology</i> , 2011, 38, 225-235.	0.8	10
506	Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines. <i>Experimental Cell Research</i> , 2011, 317, 1179-1191.	1.2	15
507	Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The Ambulatory Medical Assistance (AMA) experience. <i>International Journal of Nursing Studies</i> , 2011, 48, 926-932.	2.5	39
508	Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. <i>Blood</i> , 2011, 118, 1350-1358.	0.6	175
509	The impact of Fcγ <sub>3</sub> receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. <i>Blood</i> , 2011, 118, 4657-4662.	0.6	61

#	ARTICLE	IF	CITATIONS
510	Long-term follow-up of EBV-positive lymphoproliferative disorders in a patient with systemic lupus erythematosus. <i>Medical Molecular Morphology</i> , 2011, 44, 237-241.	0.4	2
511	Complete remission of primary bilateral adrenal lymphoma achieved by Rituximab-CHOP chemotherapy. <i>Open Medicine (Poland)</i> , 2011, 6, 778-782.	0.6	0
512	Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. <i>Annals of Oncology</i> , 2011, 22, 1839-1844.	0.6	81
513	Non-cancer mortality among people diagnosed with lymphohaematopoietic neoplasm in Australia. <i>Cancer Causes and Control</i> , 2011, 22, 715-723.	0.8	2
514	Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. <i>Journal of Gastroenterology</i> , 2011, 46, 9-16.	2.3	84
515	Retrospective analysis of hepatitis B virus reactivation after rituximab combination chemotherapy in patients with B-cell lymphoma. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 721-725.	0.1	0
516	Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab®) for Patients with Non-Hodkin's Lymphoma. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 300-305.	1.0	6
517	Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Annals of Hematology</i> , 2011, 90, 797-802.	0.8	71
518	Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. <i>Annals of Hematology</i> , 2011, 90, 809-818.	0.8	114
519	Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with 131I-anti-CD20 antibody and stem cell rescue. <i>Annals of Hematology</i> , 2011, 90, 1307-1315.	0.8	15
520	Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2011, 90, 1145-1151.	0.8	40
521	Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1135-1143.	1.1	4
522	Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1075-1080.	1.1	1
523	Clinical features and treatment outcomes of 14 cases of primary ovarian non-Hodgkin's lymphoma: a single-center experience. <i>Medical Oncology</i> , 2011, 28, 1559-1564.	1.2	17
524	High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma. <i>International Journal of Hematology</i> , 2011, 93, 720-726.	0.7	15
525	An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma. <i>International Journal of Hematology</i> , 2011, 94, 90-96.	0.7	10
526	Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors. <i>International Journal of Hematology</i> , 2011, 94, 178-184.	0.7	19
527	Antibody therapy for Adult T-cell leukemia lymphoma. <i>International Journal of Hematology</i> , 2011, 94, 443-452.	0.7	42

#	ARTICLE	IF	CITATIONS
528	Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP. <i>Pathology and Oncology Research</i> , 2011, 17, 243-247.	0.9	13
529	Primary Colorectal Lymphomaâ€”Clinical Outcomes in a Population-Based Series. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1851-1857.	0.9	22
530	Radiotherapy and "new" drugs-new side effects?. <i>Radiation Oncology</i> , 2011, 6, 177.	1.2	53
531	High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2011, 4, 31.	6.9	66
532	Intensive care of the cancer patient: recent achievements and remaining challenges. <i>Annals of Intensive Care</i> , 2011, 1, 5.	2.2	245
533	Antiâ€”CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. <i>American Journal of Hematology</i> , 2011, 86, 278-291.	2.0	21
534	Racial differences in the presentation and outcomes of diffuse large Bâ€”cell lymphoma in the United States. <i>Cancer</i> , 2011, 117, 2530-2540.	2.0	125
535	Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. <i>Leukemia Research</i> , 2011, 35, 787-792.	0.4	52
536	Predictive Value of Initial <sup>18</sup> F-FLT Uptake in Patients with Aggressive Non-Hodgkin Lymphoma Receiving R-CHOP Treatment. <i>Journal of Nuclear Medicine</i> , 2011, 52, 690-696.	2.8	65
537	Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 317-320.	0.6	3
538	Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily. <i>Leukemia and Lymphoma</i> , 2011, 52, 400-408.	0.6	15
539	Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2011, 46, 923-928.	1.3	14
540	Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis. <i>Leukemia and Lymphoma</i> , 2011, 52, 194-204.	0.6	9
541	Improving Relative Survival, But Large Remaining Differences in Survival for Non-Hodgkin's Lymphoma Across Europe and the United States From 1990 to 2004. <i>Journal of Clinical Oncology</i> , 2011, 29, 192-199.	0.8	21
542	Chemotherapy Versus Surgery in Primary B-Cell Lymphoma Masquerading as Klatzkin Tumorâ€”A Diagnostic and Therapeutic Dilemma. <i>American Journal of Therapeutics</i> , 2011, 18, e255-e257.	0.5	4
543	Relevance of the International Prognostic Index in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2011, 29, e14-e14.	0.8	13
544	Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphomaâ€”. <i>BioDrugs</i> , 2011, 25, 55-61.	2.2	11
545	Risk of Second Malignant Neoplasm Among Patients With Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3834-3834.	0.8	3

#	ARTICLE	IF	CITATIONS
546	Impact of Dose-Dense Immunochemotherapy on Prognosis of Germinal Center and Non Germinal Center Origin of Diffuse Large B Cell Lymphoma. <i>Journal of Chemotherapy</i> , 2011, 23, 227-231.	0.7	1
547	Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 174-185.	0.8	99
548	Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens. <i>Journal of Immunology</i> , 2011, 186, 6044-6055.	0.4	93
549	Tissue Microarrays in Diffuse Large B-Cell Lymphomas. <i>International Journal of Surgical Pathology</i> , 2011, 19, 417-424.	0.4	1
550	A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. <i>ISRN Hematology</i> , 2011, 2011, 1-14.	1.6	111
551	High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab. <i>Acta Haematologica</i> , 2011, 126, 44-51.	0.7	48
553	Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. <i>Annals of Oncology</i> , 2011, 22, 1845-1858.	0.6	76
554	More Randomization in Phase II Trials: Necessary but not Sufficient. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1075-1077.	3.0	16
555	Time To Remember To Forget Dose-Intensification in Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3954-3956.	0.8	5
556	Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. <i>Annals of Oncology</i> , 2011, 22, 1859-1864.	0.6	123
557	Reply to V. Pitini et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 3834-3835.	0.8	2
558	Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. <i>Leukemia</i> , 2011, 25, 1877-1881.	3.3	96
559	Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 1904-1912.	0.6	25
560	Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. <i>Future Oncology</i> , 2011, 7, 9-14.	1.1	4
561	Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 690-697.	0.8	300
562	Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1867-1872.	0.6	43
563	A Long-term Follow-up Study of Prospective 80%-dose CHOP Followed by Involved-field Radiotherapy in Elderly Lymphoma Patients. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 764-769.	0.6	1
564	Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. <i>Annals of Oncology</i> , 2011, 22, 1392-1403.	0.6	38

#	ARTICLE	IF	CITATIONS
565	New Targets and Targeted Drugs for the Treatment of Cancer: An Outlook to Pediatric Oncology. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 539-555.	0.3	9
566	Monoclonal antibodies in hematological malignancies: Past, present and future. <i>Journal of Cancer Research and Therapeutics</i> , 2011, 7, 399.	0.3	16
567	Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2011, 46, 827-834.	1.3	15
568	Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. <i>Bone Marrow Transplantation</i> , 2011, 46, 262-266.	1.3	15
569	Diffuse large B-cell lymphoma: update on therapy and prognosis. <i>Clinical Investigation</i> , 2011, 1, 989-997.	0.0	0
570	The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-10.	0.6	7
571	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. <i>Oncologist</i> , 2012, 17, 239-249.	1.9	105
572	Use of interim [ <sup>18</sup> F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 263-269.	0.6	25
573	Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. <i>Leukemia and Lymphoma</i> , 2012, 53, 973-981.	0.6	22
574	Non-Hodgkin's Lymphomas. , 2012, , 1218-1228.		1
575	Interim [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab. <i>Journal of Clinical Oncology</i> , 2012, 30, 184-190.	0.8	152
576	Treatment of Diffuse Large B-cell Lymphoma. , 2012, 17, 90-97.		0
577	Maintenance therapy in diffuse large B-cell lymphoma. <i>Current Opinion in Oncology</i> , 2012, 24, 461-465.	1.1	9
578	Chemotherapy Alone for Localized Diffuse Large B-Cell Lymphoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 421-426.	1.0	21
579	Survival from common and rare cancers in Germany in the early 21st century. <i>Annals of Oncology</i> , 2012, 23, 472-479.	0.6	81
580	Concurrent Administration of Rituximab and CHOP Chemotherapeutic Agents for Outpatients with CD20-positive Lymphoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 829-834.	0.9	0
581	Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. <i>Leukemia and Lymphoma</i> , 2012, 53, 1494-1500.	0.6	22
582	Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1859-1866.	0.6	1

#	ARTICLE	IF	CITATIONS
583	Special delivery: getting radiation to the target in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 751-753.	0.6	0
584	Clinical Presentation, Treatment, and Outcomes Among 65 Patients with HIV-Associated Lymphoma Treated at the University of North Carolina, 2000-2010. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 798-805.	0.5	18
585	Rituximab in treatment of primary gastric diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 2175-2181.	0.6	10
586	CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. <i>Annals of Oncology</i> , 2012, 23, 1267-1273.	0.6	97
587	Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 552-560.	0.7	13
588	Utility of Routine Left Ventricular Ejection Fraction Measurement Before Anthracycline-Based Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Oncology Practice</i> , 2012, 8, 336-340.	2.5	18
589	Primary central nervous system lymphoma. , 2012, , 779-806.		0
590	Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 2290-2292.	0.6	25
591	Disparities in the Early Adoption of Chemoimmunotherapy for Diffuse Large B-cell Lymphoma in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1520-1530.	1.1	76
592	Diagnosis and treatment of diffuse large B-cell lymphoma. <i>Swiss Medical Weekly</i> , 2012, 142, w13511.	0.8	27
593	Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. <i>Leukemia and Lymphoma</i> , 2012, 53, 836-841.	0.6	34
594	Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?. <i>Oncologist</i> , 2012, 17, 1562-1573.	1.9	41
595	The evaluation and optimal use of rituximab in lymphoid malignancies. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 1.	1.2	2
596	Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, 2012, 87.	1.2	17
597	Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 807-811.	0.6	11
598	Novel Therapies for Aggressive B-Cell Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-22.	0.6	16
599	Lenalidomide in Diffuse Large B-Cell Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-8.	0.6	18
600	Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare. <i>Journal of Cancer Epidemiology</i> , 2012, 2012, 1-13.	0.5	20



#	ARTICLE	IF	CITATIONS
601	Advances in the diagnosis and management of lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 29.	1.2	3
602	New developments in the management of diffuse large B-cell lymphoma. <i>Hematology</i> , 2012, 17, s93-s97.	0.7	36
603	Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin's lymphoma in a developing country?. <i>Hematology</i> , 2012, 17, 193-197.	0.7	6
604	Childhood Non-Hodgkin Lymphoma. , 2012, , 299-328.		2
605	Hematopoietic Cell Transplantation for B-Cell Lymphoma: An Update. <i>Cancer Control</i> , 2012, 19, 175-186.	0.7	9
606	Characteristics and Prognosis of B-cell Lymphoma in HIV-infected Children in the HAART Era. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e282-e288.	0.3	7
608	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. <i>Blood</i> , 2012, 119, 3698-3704.	0.6	125
609	A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. <i>Blood</i> , 2012, 120, 1210-1217.	0.6	58
610	The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. <i>Blood</i> , 2012, 119, 3276-3284.	0.6	218
611	Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. <i>Blood</i> , 2012, 120, 3222-3228.	0.6	85
612	Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20 <sup>+</sup> Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 4462-4469.	0.8	248
613	The future role of monoclonal antibody therapy in childhood acute leukaemias. <i>British Journal of Haematology</i> , 2012, 159, 3-17.	1.2	20
614	High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. <i>European Journal of Haematology</i> , 2012, 89, 395-402.	1.1	11
615	Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. <i>British Journal of Haematology</i> , 2012, 159, 39-49.	1.2	83
616	CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 15-22.	1.9	64
617	Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). <i>Lancet Oncology</i> , The, 2012, 13, 1250-1259.	5.1	217
618	Non-Hodgkin lymphoma. <i>Lancet</i> , The, 2012, 380, 848-857.	6.3	522
619	Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. <i>Critical Care</i> , 2012, 16, 231.	2.5	138

#	ARTICLE	IF	CITATIONS
620	Linfomas no Hodgkin: diagnóstico y tratamiento. EMC - Tratado De Medicina, 2012, 16, 1-6.	0.0	0
621	My Treatment Approach to Patients With Diffuse Large B-Cell Lymphoma. Mayo Clinic Proceedings, 2012, 87, 161-171.	1.4	58
622	Absolute lymphocyte count at day +21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. Leukemia and Lymphoma, 2012, 53, 1757-1763.	0.6	10
623	Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2012, 53, 725-727.	0.6	3
624	Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood, 2012, 119, 3757-3766.	0.6	72
625	Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2012, 30, 1553-1561.	0.8	430
626	A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica, 2012, 97, 758-765.	1.7	153
627	Double-Hit Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2012, 30, 3439-3443.	0.8	81
628	Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood, 2012, 119, 1882-1887.	0.6	163
629	Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands, 1989-2007. Annals of Oncology, 2012, 23, 171-182.	0.6	25
630	Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii78-vii82.	0.6	119
631	R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Annals of Oncology, 2012, 23, 147-153.	0.6	60
632	Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leukemia and Lymphoma, 2012, 53, 1999-2003.	0.6	28
633	The Evolving Role of Stem Cell Transplants in Lymphomas. Biology of Blood and Marrow Transplantation, 2012, 18, 660-673.	2.0	28
634	Autologous or allogeneic transplantation in B- and T-cell lymphomas. Best Practice and Research in Clinical Haematology, 2012, 25, 61-73.	0.7	1
635	Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008-2012. Cancer Epidemiology, 2012, 36, e19-e25.	0.8	19
636	Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma. BMC Gastroenterology, 2012, 12, 77.	0.8	14
637	Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting. Cancer Cell International, 2012, 12, 38.	1.8	8

#	ARTICLE	IF	CITATIONS
638	Splenic irradiation-induced gastric variceal bleeding in a primary splenic diffuse large B-cell lymphoma patient: a rare complication successfully treated by splenectomy with short gastric vein ligation. <i>World Journal of Surgical Oncology</i> , 2012, 10, 150.	0.8	2
639	CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: A matched case-control analysis in a single institution. <i>Journal of Translational Medicine</i> , 2012, 10, 84.	1.8	23
640	Homozygous A polymorphism of the complement C1qA 276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP. <i>Journal of Hematology and Oncology</i> , 2012, 5, 51.	6.9	25
641	Novel CD20 monoclonal antibodies for lymphoma therapy. <i>Journal of Hematology and Oncology</i> , 2012, 5, 64.	6.9	116
643	The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 1731-1739.	0.8	31
645	Diffuse large B cell lymphoma: molecular targeted therapy. <i>International Journal of Hematology</i> , 2012, 96, 552-561.	0.7	19
646	Severe hepatitis associated with varicella zoster virus infection in a patient with diffuse large B cell lymphoma treated with rituximab-CHOP chemotherapy. <i>International Journal of Hematology</i> , 2012, 96, 516-520.	0.7	8
648	Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation. <i>Annals of Hematology</i> , 2012, 91, 1907-1915.	0.8	6
649	Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. <i>Annals of Hematology</i> , 2012, 91, 1741-1745.	0.8	34
650	Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study. <i>Annals of Hematology</i> , 2012, 91, 1747-1756.	0.8	14
651	The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 1383-1391.	0.8	39
652	Cost Effectiveness of Rituximab for Non-Hodgkin's Lymphoma. <i>Pharmacoeconomics</i> , 2012, 30, 537-549.	1.7	9
653	The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. <i>Radiology and Oncology</i> , 2012, 46, 153-9.	0.6	8
654	Lymphoproliferative Disorders in Patients with Systemic Lupus Erythematosus. , 0, , .		0
655	A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas. <i>The Korean Journal of Hematology</i> , 2012, 47, 53.	0.7	12
656	Early Relapse is Associated with the High Serum Soluble Interleukin-2 Receptor Level after the Sixth Cycle of R-CHOP Chemotherapy in Patients with Advanced Diffuse Large B-Cell Lymphoma. <i>Annals of Oncology</i> , 2012, 23, xi143.	0.6	0
657	Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease. <i>Current Drug Delivery</i> , 2012, 9, 41-51.	0.8	4
658	Treatment of Diffuse Large B Cell Lymphoma. <i>Korean Journal of Internal Medicine</i> , 2012, 27, 369.	0.7	24

#	ARTICLE	IF	CITATIONS
659	Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab. <i>Oncology Letters</i> , 2012, 4, 541-545.	0.8	4
660	Clinical characteristics and outcomes of primary bone lymphoma in Korea. <i>The Korean Journal of Hematology</i> , 2012, 47, 213.	0.7	12
661	Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study. <i>Experimental and Therapeutic Medicine</i> , 2012, 4, 475-480.	0.8	12
662	Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012, 34, 447-451.	0.7	21
663	Anti-CD20 Antibody Therapy for B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2012, 366, 2008-2016.	13.9	264
664	Matchedâ€pair analysis comparing the outcomes of primary breast and nodal diffuse large Bâ€cell lymphoma in patients treated with rituximab plus chemotherapy. <i>International Journal of Cancer</i> , 2012, 131, 235-243.	2.3	47
665	The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 937-940.	2.0	40
666	Limitedâ€stage diffuse large Bâ€cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy. <i>Cancer</i> , 2012, 118, 4156-4165.	2.0	49
667	Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIVâ€associated nonâ€Hodgkin lymphoma. <i>Cancer</i> , 2012, 118, 3977-3983.	2.0	81
668	A randomized study comparing yttriumâ€90 ibritumomab tiuxetan (Zevalin) and highâ€dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. <i>Cancer</i> , 2012, 118, 4706-4714.	2.0	98
669	Comparative effectiveness and cost of adding rituximab to firstâ€line chemotherapy for elderly patients diagnosed with diffuse large Bâ€cell lymphoma. <i>Cancer</i> , 2012, 118, 6079-6088.	2.0	28
670	Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2012, 13, 82-101.	1.3	4
671	Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. <i>Annals of Hematology</i> , 2012, 91, 697-703.	0.8	130
672	Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. <i>Annals of Hematology</i> , 2012, 91, 705-714.	0.8	58
673	Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. <i>Annals of Hematology</i> , 2012, 91, 837-845.	0.8	26
674	Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL. <i>Annals of Hematology</i> , 2012, 91, 997-1005.	0.8	24
675	Successful treatment of primary malignant lymphoma of the penis by organ-preserving rituximab-containing chemotherapy. <i>International Journal of Clinical Oncology</i> , 2012, 17, 181-184.	1.0	14
676	High Kiâ€67 expression in diffuse large Bâ€cell lymphoma patients with nonâ€germinal center subtype indicates limited survival benefit from Râ€CHOP therapy. <i>European Journal of Haematology</i> , 2012, 88, 510-517.	1.1	39

#	ARTICLE	IF	CITATIONS
677	The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia Research</i> , 2012, 36, 413-417.	0.4	45
678	Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. <i>Leukemia Research</i> , 2012, 36, 749-755.	0.4	8
679	<i>VEGFA</i> and <i>VEGFR2</i> genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. <i>Cancer Science</i> , 2012, 103, 497-503.	1.7	33
680	Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Cancer Science</i> , 2012, 103, 933-938.	1.7	61
681	Impact of rituximab on treatment outcomes of patients with diffuse large B-cell lymphoma: a population-based analysis. <i>British Journal of Haematology</i> , 2012, 158, 481-488.	1.2	37
682	Clinical behavior and treatment outcome of primary nasal diffuse large B-cell lymphoma. <i>Cancer</i> , 2012, 118, 1593-1598.	2.0	20
683	Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 375-382.	0.8	23
684	Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan. <i>Annals of Hematology</i> , 2012, 91, 383-390.	0.8	39
685	Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors. <i>Annals of Hematology</i> , 2012, 91, 391-397.	0.8	25
686	Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry. <i>Annals of Hematology</i> , 2012, 91, 561-570.	0.8	11
687	Acute painful lumbosacral paresthesia after intrathecal rituximab. <i>Journal of Neurology</i> , 2012, 259, 559-561.	1.8	7
688	Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients. <i>Transfusion</i> , 2013, 53, 115-122.	0.8	4
689	Periampullary Lymphoma Masquerading as Adenocarcinoma. <i>Indian Journal of Surgical Oncology</i> , 2013, 4, 155-157.	0.3	0
690	Available evidence and outcome of off-label use of rituximab in clinical practice. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1689-1699.	0.8	16
692	End-of-Life Care in Hematology: Update From Australia. <i>Journal of Social Work in End-of-Life and Palliative Care</i> , 2013, 9, 96-110.	0.4	17
693	Resistance to Immunotherapeutic Antibodies in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , .	0.1	2
694	Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. <i>Cancer</i> , 2013, 119, 3672-3679.	2.0	55
695	Actualit�s th�rapeutiques dans les lymphomes. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
696	Non-Hodgkin Lymphoma. , 2013, , .		1
697	Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2013, 61, 165-174.	1.0	2
698	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. <i>Supportive Care in Cancer</i> , 2013, 21, 3243-3254.	1.0	46
699	Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma. <i>Supportive Care in Cancer</i> , 2013, 21, 1145-1152.	1.0	18
700	The Role of Radiation Therapy in the Treatment of Stage I-II Diffuse Large B-Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 236-242.	1.2	11
701	Large Cell Lymphoma: Correlation of HIV Status and Prognosis with Differentiation Profiles Assessed by Immunophenotyping. <i>Pathology and Oncology Research</i> , 2013, 19, 695-705.	0.9	14
702	Correlation Between Immunophenotype Classification and Clinicopathological Features in Chinese Patients with Primary Gastric Diffuse Large B-Cell Lymphoma. <i>Pathology and Oncology Research</i> , 2013, 19, 317-322.	0.9	3
703	Aggressive lymphoma at ASH 2012: new standards and new perspectives. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 170-173.	0.3	1
704	Point prevalence of <i>Pneumocystis pneumonia</i> in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy. <i>Annals of Hematology</i> , 2013, 92, 231-238.	0.8	26
705	Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. <i>Blood</i> , 2013, 121, 278-285.	0.6	80
706	Treatment and Outcomes in Patients With Primary Cutaneous B-Cell Lymphoma: The BC Cancer Agency Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 719-725.	0.4	65
707	Prospective phase II study of rituximab with alternating cycles of hyperfractionated cyclophosphamide, vincristine, and doxorubicin with high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 611-620.	1.2	23
708	The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL). <i>Bone Marrow Transplantation</i> , 2013, 48, 1271-1278.	1.3	11
709	Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: An investigation of clinical and histopathological features. <i>Acta Ophthalmologica</i> , 2013, 91, 1-27.	0.6	37
710	Combination of YM155, a survivin suppressant with a STAT3 inhibitor: A new strategy to treat diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2013, 37, 1156-1161.	0.4	17
711	Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?. <i>International Journal of Hematology</i> , 2013, 98, 664-671.	0.7	14
712	Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. <i>Lancet Oncology</i> , The, 2013, 14, e548-e561.	5.1	21
713	Infectiologie en rĂ©animation. <i>RĂ©fĂ©rences En RĂ©animation</i> , 2013, , .	0.0	1

#	ARTICLE	IF	CITATIONS
714	Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 12-27.	2.0	19
715	Primary Breast Diffuse Large B Cell Lymphoma – Report of 6 Cases from South India with Review of Literature. <i>Indian Journal of Surgical Oncology</i> , 2013, 4, 368-373.	0.3	8
716	Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). <i>Annals of Oncology</i> , 2013, 24, 1032-1037.	0.6	31
718	Lymphomes non hodgkiniens primitifs du cavum : À propos de 32 cas pris en charge À l'Institut national d'oncologie (Rabat, Maroc) entre 1997 et 2009. <i>Journal Africain Du Cancer</i> , 2013, 5, 51-56.	0.1	0
719	High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?. <i>Leukemia and Lymphoma</i> , 2013, 54, 2575-2576.	0.6	4
720	Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study. <i>Leukemia and Lymphoma</i> , 2013, 54, 743-751.	0.6	12
721	Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2627-2630.	0.6	5
722	Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement. <i>Journal of Clinical Oncology</i> , 2013, 31, 4115-4122.	0.8	95
723	The risk of CNS involvement in aggressive lymphomas in the rituximab era. <i>Expert Review of Hematology</i> , 2013, 6, 643-652.	1.0	1
725	Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. <i>Annals of Oncology</i> , 2013, 24, 2236-2244.	0.6	94
726	Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013, 31, 314-320.	0.8	152
727	Three prognostic factors influence clinical outcomes of primary testicular lymphoma. <i>Tumor Biology</i> , 2013, 34, 55-63.	0.8	24
728	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
729	Children's Oncology Group's 2013 blueprint for research: Non-Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 979-984.	0.8	35
730	Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 106-111.	0.2	246
731	Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 277-283.	0.6	43
732	Diffuse large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 146-171.	2.0	323
733	Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). <i>Leukemia Research</i> , 2013, 37, 1420-1428.	0.4	41

#	ARTICLE	IF	CITATIONS
734	Experience with B-cell lymphoma at a South African centre in the HIV Era. <i>Transfusion and Apheresis Science</i> , 2013, 49, 31-39.	0.5	7
735	Tissue microarray in a subset of South African patients with DLBCL. <i>Transfusion and Apheresis Science</i> , 2013, 49, 120-132.	0.5	1
736	Therapy for diffuse large B-cell lymphoma: getting personal. <i>Lancet, The</i> , 2013, 381, 1793-1794.	6.3	6
737	Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2606-2612.	0.6	14
738	Non-Hodgkin Lymphomas Presenting as Soft Tissue Masses: A Single Center Experience and Meta-Analysis of the Published Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 258-265.	0.2	21
739	Lymphoma studies by the Australasian Leukaemia and Lymphoma Group. <i>Transfusion and Apheresis Science</i> , 2013, 49, 110-112.	0.5	0
740	Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 123-128.	2.0	19
741	Allogeneic stem cell transplantation for diffuse large B cell lymphoma: Defining the role of allografts. <i>Transfusion and Apheresis Science</i> , 2013, 49, 63-71.	0.5	1
742	Phase I study of obinutuzumab (<sc>GA</sc>101) in <sc>J</sc>apanese patients with relapsed or refractory <sc>B</sc>-cell non- <i>H&lt;/i&gt;-odgkin lymphoma. <i>Cancer Science</i>, 2013, 104, 105-110.</i>	1.7	31
743	Primary prophylaxis of bacterial infections and <i>Pneumocystis jirovecii</i> pneumonia in patients with hematological malignancies and solid tumors. <i>Annals of Hematology</i> , 2013, 92, 433-442.	0.8	112
744	Immunology of the Lymphomas. , 2013, , 919-943.		0
745	Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions. <i>Drugs</i> , 2013, 73, 439-461.	4.9	10
746	R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 161, 383-388.	1.2	23
747	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. <i>Lancet, The</i> , 2013, 381, 1817-1826.	6.3	450
748	Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia Research</i> , 2013, 37, 386-391.	0.4	6
749	Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. <i>OncoTargets and Therapy</i> , 2013, 6, 289.	1.0	14
750	Renewed interest in the role of consolidative radiotherapy in advanced stage diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2122-2130.	0.6	16
751	Non-Hodgkin's B-cell lymphoma: Advances in molecular strategies targeting drug resistance. <i>Experimental Biology and Medicine</i> , 2013, 238, 971-990.	1.1	52



#	ARTICLE	IF	CITATIONS
752	Prognostic implications of tumor extent in early-stage diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2013, 97, 232-239.	0.7	1
753	Long-Term Remission After Multiple Relapses in an Elderly Patient With Lymphomatoid Granulomatosis After Rituximab and High-Dose Cytarabine Chemotherapy Without Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, e390-e393.	0.8	7
754	Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?. <i>Leukemia and Lymphoma</i> , 2013, 54, 934-939.	0.6	5
755	Clinical features of de novo CD25 <sup>+</sup> diffuse large B-cell lymphoma. <i>Hematology</i> , 2013, 18, 14-19.	0.7	8
756	Rituximab in the treatment of diffuse large B-cell lymphoma primary of the lung. <i>Hematology</i> , 2013, 18, 81-84.	0.7	8
757	Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: a single-center experience. <i>Hematology</i> , 2013, 18, 74-80.	0.7	4
759	Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 43-57.	1.1	18
760	A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement. <i>Haematologica</i> , 2013, 98, 1242-1249.	1.7	3
761	Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. <i>Annals of Oncology</i> , 2013, 24, 1385-1392.	0.6	99
762	Examining racial differences in diffuse large B-cell lymphoma presentation and survival. <i>Leukemia and Lymphoma</i> , 2013, 54, 268-276.	0.6	50
763	Prognostic significance of hypoxia inducible factor-1 $\alpha$ and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab. <i>Leukemia and Lymphoma</i> , 2013, 54, 959-966.	0.6	9
764	Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. <i>Leukemia and Lymphoma</i> , 2013, 54, 979-985.	0.6	20
765	The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	16
766	Antibody Therapy of Pediatric B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2013, 3, 68.	1.3	3
767	Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogeneously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment. <i>Nuclear Medicine Communications</i> , 2013, 34, 946-952.	0.5	27
768	A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination With Rituximab in Patients With Non-Hodgkin Lymphoma. <i>Journal of Immunotherapy</i> , 2013, 36, 331-341.	1.2	30
769	Selective Immunophenotyping for Diagnosis of B-cell Neoplasms. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 116-131.	0.6	35
770	Clinical assessment for identifying causes of acute respiratory failure in cancer patients. <i>European Respiratory Journal</i> , 2013, 42, 435-443.	3.1	45

#	ARTICLE	IF	CITATIONS
771	Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma Patients. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1078-1085.	3.0	29
772	Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. <i>Annals of Oncology</i> , 2013, 24, 428-432.	0.6	36
773	Comparison of the efficacy and safety of Rituximab (Mabthera <sup>®</sup> ) and its biosimilar (Reditux <sup>®</sup> ) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 292.	0.1	41
774	Intrapericardial and Intrapleural Administration of Rituximab to a Patient with Marginal Zone Lymphoma. <i>Acta Haematologica</i> , 2013, 130, 169-171.	0.7	0
775	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 53-57.	0.6	42
776	Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2013, 24, 1603-1609.	0.6	28
777	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 1164-1171.	0.8	92
778	Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study. <i>ISRN Hematology</i> , 2013, 2013, 1-9.	1.6	8
779	Stratégie diagnostique devant une insuffisance respiratoire aiguë chez un patient atteint d'onco-hématologie admis en réanimation. <i>Revue Française de Réanimation</i> , 2013, , 463-489.	0.0	0
780	Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large cell lymphoma. <i>European Journal of Haematology</i> , 2013, 90, 195-201.	1.1	18
781	The lymphocyte to monocyte ratio improves the IPI risk definition of diffuse large B cell lymphoma when rituximab is added to chemotherapy. <i>American Journal of Hematology</i> , 2013, 88, 1062-1067.	2.0	54
782	Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. <i>British Journal of Haematology</i> , 2013, 163, 168-181.	1.2	50
783	Outcomes of patients with relapsed/refractory diffuse large B cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. <i>American Journal of Hematology</i> , 2013, 88, 890-894.	2.0	108
784	Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B cell lymphoma treated with the R-CHOP regimen. <i>European Journal of Haematology</i> , 2013, 91, 322-331.	1.1	15
785	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. <i>Pharmacological Reviews</i> , 2013, 65, 1351-1395.	7.1	33
786	Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2103-2109.	0.8	149
787	The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. <i>Oncologist</i> , 2013, 18, 625-633.	1.9	31
788	Pixantrone: merging safety with efficacy. <i>Expert Review of Hematology</i> , 2013, 6, 25-33.	1.0	3

#	ARTICLE	IF	CITATIONS
789	The role of monoclonal antibodies in the treatment of lymphomas. Expert Opinion on Biological Therapy, 2013, 13, 227-239.	1.4	4
790	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood, 2013, 122, 1137-1143.	0.6	120
791	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood, 2013, 122, 3251-3262.	0.6	156
792	Treatment strategies for aggressive lymphomas: what works?. Hematology American Society of Hematology Education Program, 2013, 2013, 584-590.	0.9	33
793	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica, 2013, 98, 1732-1738.	1.7	54
794	Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma. Blood Research, 2013, 48, 266.	0.5	16
796	Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry. Blood Research, 2013, 48, 115.	0.5	5
797	Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. Current Biomarker Findings, 0, , 17.	0.4	1
798	Comparison of Cancer Care and Outcomes between a Public Safety-Net Hospital and a Private Cancer Center. Journal of Health Care for the Poor and Underserved, 2013, 24, 1136-1149.	0.4	8
799	Prognostic Importance of the Soluble Form of IL-2 Receptor $\alpha$ (sIL-2R $\alpha$ ) and its Relationship with Surface Expression of IL-2R $\alpha$ (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases. Journal of Clinical and Experimental Hematopathology: JCEH, 2013, 53, 197-205.	0.3	14
800	Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2013, 53, 121-125.	0.3	12
801	Primary lymphoma of the colon. Revista Espanola De Enfermedades Digestivas, 2013, 105, 79-83.	0.1	16
802	Lymphoma in the immunosuppressed. , 0, , 273-285.		0
803	Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients. Journal of Cancer Research, 2014, 2014, 1-7.	0.7	0
804	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth. Obstetrics and Gynecology Science, 2014, 57, 526.	0.6	27
805	Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood Research, 2014, 49, 162.	0.5	15
806	Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems. Journal of Korean Medical Science, 2014, 29, 53.	1.1	26
807	Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. Journal of Korean Medical Science, 2014, 29, 1493.	1.1	21

#	ARTICLE	IF	CITATIONS
808	Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma. Brazilian Journal of Pharmaceutical Sciences, 2014, 50, 445-455.	1.2	0
809	Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection. Blood Research, 2014, 49, 115.	0.5	3
810	Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen. Journal of Clinical and Experimental Hematopathology: JCEH, 2014, 54, 117-127.	0.3	4
811	Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget, 2014, 5, 7368-7380.	0.8	7
812	Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2014, 55, 2428-2437.	0.6	8
813	Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. Journal of Clinical Oncology, 2014, 32, 4127-4133.	0.8	79
814	Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens. Leukemia, 2014, 28, 2260-2263.	3.3	8
815	Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey. Pharmaceuticals, 2014, 7, 530-544.	1.7	58
816	PRIMARY MEDIASTINAL B LARGE CELL LYMPHOMA - CASE REPORT. Acta Medica Medianae, 2014, , 46-53.	0.0	0
817	Optimal disease surveillance strategies in non-Hodgkin lymphoma. Hematology American Society of Hematology Education Program, 2014, 2014, 481-487.	0.9	12
818	R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica, 2014, 99, 1343-1349.	1.7	79
819	Childhood and Adolescent B-Cell Lymphoma: Bench to Bedside and Back to Bench. , 2014, , 247-285.		0
820	Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Emerging Drugs, 2014, 19, 367-383.	1.0	4
821	Prospective International Cohort Study Demonstrates Inability of Interim PET to Predict Treatment Failure in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2014, 55, 1936-1944.	2.8	63
822	Gene expression profiles of central nervous system lymphoma predict poor survival in patients with diffuse large B-cell lymphoma. British Journal of Haematology, 2014, 166, 794-797.	1.2	3
823	Parenthood in long-term survivors after <scp>CHOP</scp> with or without etoposide treatment for aggressive lymphoma. British Journal of Haematology, 2014, 166, 612-615.	1.2	7
824	Humoral and Cellular Immunotherapy in ALL in Children, Adolescents, and Young Adults. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S6-S13.	0.2	8
825	Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 168-174.	0.7	42

#	ARTICLE	IF	CITATIONS
826	Young Patients With Nonâ€“Germinal Center B-Cellâ€“Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , 2014, 32, 3996-4003.	0.8	79
827	Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous Bâ€“cell lymphomas. <i>European Journal of Haematology</i> , 2014, 93, 129-136.	1.1	25
828	A phase III randomized trial of highâ€“dose CEOPâ€“+â€“filgrastim versus standardâ€“dose CEOP in patients with nonâ€“Hodgkin lymphoma: 10â€“year followâ€“up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. <i>American Journal of Hematology</i> , 2014, 89, 536-541.	2.0	8
829	Adolescents and Young Adults with Non-Hodgkin's Lymphoma: Slipping between the Cracks. <i>Acta Haematologica</i> , 2014, 132, 279-291.	0.7	5
830	Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2521.	3.8	195
831	Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3Î²) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. <i>Experimental Hematology and Oncology</i> , 2014, 3, 31.	2.0	1
832	High Concordance of Gene Expression Profilingâ€“correlated Immunohistochemistry Algorithms in Diffuse Large B-cell Lymphoma, Not Otherwise Specified. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1046-1057.	2.1	33
833	Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. <i>Nutrition and Cancer</i> , 2014, 66, 225-233.	0.9	47
834	Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. <i>Current Opinion in Hematology</i> , 2014, 21, 297-308.	1.2	8
835	Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 1814-1822.	3.2	35
836	Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. <i>Annals of Oncology</i> , 2014, 25, 1800-1806.	0.6	60
837	Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. <i>Therapeutic Advances in Hematology</i> , 2014, 5, 3-12.	1.1	17
838	Treatment Patterns and Comparative Effectiveness in Elderly Diffuse Large B-Cell Lymphoma Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Oncologist</i> , 2014, 19, 1249-1257.	1.9	54
839	Leitsymptom. , 2014, , 67-100.		0
840	R-CHOP: Does One Size Fit All in Diffuse Large B Cell Lymphoma?. <i>Acta Haematologica</i> , 2014, 131, 153-155.	0.7	0
841	Management of relapsed-refractory diffuse large B cell lymphoma. <i>South Asian Journal of Cancer</i> , 2014, 03, 066-070.	0.2	53
842	Lymphomas. <i>Pediatric Oncology</i> , 2014, , 251-301.	0.5	0
843	Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA. <i>Lymphoma</i> , 2014, 2014, 1-12.	0.2	13

#	ARTICLE	IF	CITATIONS
844	Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study. <i>Leukemia and Lymphoma</i> , 2014, 55, 533-537.	0.6	16
845	Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. <i>SpringerPlus</i> , 2014, 3, 5.	1.2	7
846	Survival of patients with transformed lymphoma in the rituximab era. <i>Annals of Hematology</i> , 2014, 93, 1007-1014.	0.8	34
847	Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression. <i>International Journal of Hematology</i> , 2014, 99, 79-86.	0.7	8
848	Decision Tools for Radiation Oncology. <i>Medical Radiology</i> , 2014, , .	0.0	2
849	Association of interleukin-10, tumor necrosis factor- $\alpha$ and transforming growth factor- $\beta$ gene polymorphisms with the outcome of diffuse large B-cell lymphomas. <i>International Journal of Clinical Oncology</i> , 2014, 19, 186-192.	1.0	12
850	Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP. <i>International Journal of Clinical Oncology</i> , 2014, 19, 178-185.	1.0	2
851	Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. <i>Annals of Hematology</i> , 2014, 93, 437-447.	0.8	19
852	Anthracycline cardiotoxicity and lymphoma. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 43-46.	0.3	1
853	Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. <i>Annals of Oncology</i> , 2014, 25, 2124-2133.	0.6	141
854	R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. <i>British Journal of Haematology</i> , 2014, 166, 382-389.	1.2	33
855	Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014, 25, 171-176.	0.6	48
856	A varicella outbreak in B-cell lymphoma patients receiving rituximab-containing chemotherapy. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 774-777.	0.8	12
857	A new frontier in haematology – combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 274-281.	1.1	8
858	Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2014, 92, 204-210.	1.1	55
859	The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 1291-1298.	0.4	13
860	Insights on practice variations in the management of lymphoma and leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 2449-2456.	0.6	6
861	British HIV Association guidelines for HIV-associated malignancies 2014. <i>HIV Medicine</i> , 2014, 15, 1-92.	1.0	67

#	ARTICLE	IF	CITATIONS
862	Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1112-1118.	0.8	201
863	Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma. <i>Journal of Immunology</i> , 2014, 193, 1519-1524.	0.4	46
864	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncology</i> , The, 2014, 15, 1019-1026.	5.1	246
865	Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive B-cell lymphoma/leukaemia: a Children's Oncology Group Report. <i>British Journal of Haematology</i> , 2014, 167, 394-401.	1.2	113
866	A drug safety evaluation of rituximab and risk of hepatitis B. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 977-987.	1.0	16
867	Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype. <i>Clinical Cancer Research</i> , 2014, 20, 5182-5193.	3.2	34
868	Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. <i>BMC Cancer</i> , 2014, 14, 586.	1.1	41
869	The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab. <i>Annals of Hematology</i> , 2014, 93, 1755-1764.	0.8	30
870	Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry. <i>Annals of Hematology</i> , 2014, 93, 1705-1715.	0.8	36
871	Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. <i>Annals of Hematology</i> , 2014, 93, 1735-1743.	0.8	44
872	Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy. <i>Annals of Hematology</i> , 2014, 93, 1903-1911.	0.8	9
873	The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression. <i>Journal of Hematology and Oncology</i> , 2014, 7, 34.	6.9	13
874	Diffuse large B-cell lymphoma treatment approaches in the molecular era. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 12-23.	12.5	333
875	Quercetin Potentiates the Antitumor Activity of Rituximab in Diffuse Large B-Cell Lymphoma by Inhibiting STAT3 Pathway. <i>Cell Biochemistry and Biophysics</i> , 2014, 70, 1357-1362.	0.9	13
876	Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Medical Oncology</i> , 2014, 31, 56.	1.2	12
877	From empiric to mechanism-based therapy for peripheral T cell lymphoma. <i>International Journal of Hematology</i> , 2014, 99, 249-262.	0.7	16
878	Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy. <i>International Journal of Hematology</i> , 2014, 100, 88-95.	0.7	19
879	Follow-up in aggressive lymphomas. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 80-82.	0.3	0

#	ARTICLE	IF	CITATIONS
880	Prognostic Value of Metabolic Tumor Volume Estimated by 18â€‰F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 187-195.	0.6	41
881	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119
882	Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 757-766.	5.1	95
883	Drugâ€‰drug interactions in HIV positive cancer patients. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 665-677.	2.5	15
885	Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1019-1031.	1.4	26
886	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	0.8	304
887	Therapy of HIV-associated lymphomaâ€‰recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ„), in cooperation with the German AIDS Society (DAIG). <i>Annals of Hematology</i> , 2014, 93, 913-921.	0.8	33
888	Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 1849-1853.	0.6	6
889	Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. <i>Leukemia and Lymphoma</i> , 2014, 55, 538-543.	0.6	74
890	Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e91031.	1.1	19
891	A Rare Case of Hepatic T-Cell Rich B-Cell Lymphoma (TCRBCL) in a Juvenile Dog. <i>Journal of Veterinary Medical Science</i> , 2014, 76, 1393-1397.	0.3	4
892	Neurolymphomatosis in a Patient with Extranodal NK/T-cell Lymphoma, Nasal-type: A Case Report and Literature Review. <i>Internal Medicine</i> , 2014, 53, 471-475.	0.3	10
893	Suboptimal dosing of rituximab in male and female patients with DLBCL. <i>Blood</i> , 2014, 123, 640-646.	0.6	124
894	The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. <i>Blood</i> , 2014, 124, 720-728.	0.6	33
895	Is rituximab one for all ages and each sex?. <i>Blood</i> , 2014, 123, 602-603.	0.6	7
896	Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. <i>Haematologica</i> , 2014, 99, 125-130.	1.7	77
897	Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Nonâ€‰Hodgkin's Lymphoma and Exposureâ€‰Response in CLL. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014, 3, 1-11.	1.3	71
898	Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma. <i>Oncology Letters</i> , 2015, 10, 2925-2930.	0.8	6



#	ARTICLE	IF	CITATIONS
899	HIV-infection impact on clinicalâ€“biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. <i>Aids</i> , 2015, 29, 811-818.	1.0	37
900	Prognostic significance of Epsteinâ€“Barr virus DNA detection in pretreatment serum in diffuse large Bâ€“cell lymphoma. <i>Cancer Science</i> , 2015, 106, 1576-1581.	1.7	20
901	Longitudinal risk of herpes zoster in patients with non-Hodgkin lymphoma receiving chemotherapy: A nationwide population-based study. <i>Scientific Reports</i> , 2015, 5, 14008.	1.6	16
902	Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. <i>Blood</i> , 2015, 125, 236-241.	0.6	17
903	Effects of addition of rituximab to chemotherapy on central nervous system events in patients with diffuse large B-cell lymphoma. <i>Molecular and Clinical Oncology</i> , 2015, 3, 747-752.	0.4	2
904	Radiotherapy for advanced-stage aggressive non-Hodgkin lymphoma. <i>The Cochrane Library</i> , 2015, , .	1.5	0
905	Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010. <i>Haematologica</i> , 2015, 100, 525-533.	1.7	37
906	Primary sternum diffuse large B-cell lymphoma: A case report and review of the literature. <i>Oncology Letters</i> , 2015, 9, 2623-2628.	0.8	5
907	ChÅ,oniak rozlany z duÅ¼ych limfocytÅ³w B â€“ czy R-CHOP-21 jest leczeniem optymalnym?. <i>Acta Haematologica Polonica</i> , 2015, 46, 100-106.	0.1	0
909	Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. <i>Chinese Journal of Cancer</i> , 2015, 34, 225-34.	4.9	21
910	Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015, 171, 763-775.	1.2	83
911	Treatment of pediatric lymphoma in Japan: Current status and plans for the future. <i>Pediatrics International</i> , 2015, 57, 523-534.	0.2	8
912	ACR Appropriateness CriteriaÂ® Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 610-620.	0.6	9
913	Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma. <i>Medicine (United States)</i> , 2015, 94, e993.	0.4	49
914	The use of Yttrium-90 Ibritumomab Tiuxetan ( 90 Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation. <i>Wspolczesna Onkologia</i> , 2015, 1, 43-47.	0.7	2
915	Current trends in the treatment of primary mediastinal large B-cell lymphoma â€“ an overview. <i>Wspolczesna Onkologia</i> , 2015, 6, 428-435.	0.7	4
916	Clinical and biological aspects of aggressive B-cell non-Hodgkin lymphoma in adolescents and young adults. <i>Clinical Oncology in Adolescents and Young Adults</i> , 0, , 115.	0.8	1
917	Systematic review/Meta-analysis The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis. <i>Archives of Medical Science</i> , 2015, 4, 708-714.	0.4	22

#	ARTICLE	IF	CITATIONS
918	Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy. <i>Chinese Medical Journal</i> , 2015, 128, 378-383.	0.9	18
919	Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. <i>Journal of Cancer Science &amp; Therapy</i> , 2015, 7, 347-358.	1.7	34
920	The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2015, 10, e0126615.	1.1	22
921	Prophylaxis and Treatment of <i>Pneumocystis jiroveci</i> Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0122171.	1.1	59
922	Novel Pharmacodynamic Approach to Assess Obatoclox (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkinâ€™s Lymphoma. <i>Clinical Cancer Drugs</i> , 2015, 2, 44-53.	0.3	0
923	Favorable Event Free-Survival of High-Dose Chemotherapy followed by Autologous Hematopoietic Stem Cell Transplantation for Higher Risk Diffuse Large B-Cell Lymphoma in First Complete Remission. <i>Hematology Reports</i> , 2015, 7, 5812.	0.3	8
924	Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. <i>Annals of Oncology</i> , 2015, 26, 1771-1776.	0.6	20
925	Entinostat, a novel histone deacetylase inhibitor is active in Bâ€™cell lymphoma and enhances the antiâ€™tumour activity of rituximab and chemotherapy agents. <i>British Journal of Haematology</i> , 2015, 169, 506-519.	1.2	39
926	The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis. <i>Acta Haematologica</i> , 2015, 134, 111-118.	0.7	22
927	Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile. <i>Leukemia and Lymphoma</i> , 2015, 56, 65-71.	0.6	24
928	Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+non-Hodgkinâ€™s lymphoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 21-29.	1.0	4
929	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Leukemia and Lymphoma</i> , 2015, 56, 2569-2578.	0.6	36
930	A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival. <i>BMC Cancer</i> , 2015, 15, 288.	1.1	16
931	Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkinâ€™s lymphoma (B-NHL) chemotherapy: a meta-analysis. <i>Journal of Chemotherapy</i> , 2015, 27, 365-370.	0.7	17
932	Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. <i>Molecular Cancer</i> , 2015, 14, 207.	7.9	135
933	The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 676-681.	0.6	5
934	Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study. <i>Leukemia Research</i> , 2015, 39, 33-37.	0.4	5
935	Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 293-300.	0.6	7

#	ARTICLE	IF	CITATIONS
936	Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 716-724.	0.6	37
937	Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2039-2046.	0.6	12
938	Prognostic significance of the number and type of extra nodal localizations of DLBCL in the rituximab era. <i>Acta Haematologica Polonica</i> , 2015, 46, 49-55.	0.1	0
939	Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. <i>Leukemia and Lymphoma</i> , 2015, 56, 1659-1664.	0.6	24
940	Management of Diffuse Large B-Cell Lymphoma (DLBCL). <i>Cancer Treatment and Research</i> , 2015, 165, 271-288.	0.2	53
941	Utility of interim and end-of-treatment [ <sup>18</sup> F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2579-2584.	0.6	16
942	Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphoma. <i>Leukemia Research</i> , 2015, 39, 307-310.	0.4	4
943	Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. <i>Leukemia</i> , 2015, 29, 1564-1570.	3.3	54
944	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. <i>Blood</i> , 2015, 125, 22-32.	0.6	445
945	Validation of an enhanced International Prognostic Index (NCCN-IPI) in an Asian cohort of patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1063-1065.	0.8	19
946	CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis. <i>Human Pathology</i> , 2015, 46, 593-599.	1.1	32
947	Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study. <i>International Journal of Cancer</i> , 2015, 137, 658-665.	2.3	36
948	Immunoreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?. <i>Cancers</i> , 2015, 7, 305-328.	1.7	45
949	Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma. <i>Archives of Medical Research</i> , 2015, 46, 454-461.	1.5	14
950	Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 99-106.	0.4	13
951	Lymphopenia predicts preclinical relapse in the routine follow-up of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1261-1265.	0.6	4
952	Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. <i>Haematologica</i> , 2015, 100, 955-963.	1.7	75
953	Additional Support for Consolidative Radiotherapy for Diffuse Large B Cell Lymphoma in the Modern Rituximab Era. <i>Acta Haematologica</i> , 2015, 134, 109-110.	0.7	2

#	ARTICLE	IF	CITATIONS
954	Additional Survival Benefit of Involved-Lesion Radiation Therapy After R-CHOP Chemotherapy in Limited Stage Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 91-98.	0.4	22
955	Predictors of Local Recurrence After Rituximab-Based Chemotherapy Alone in Stage III and IV Diffuse Large B-Cell Lymphoma: Guiding Decisions for Consolidative Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 107-112.	0.4	24
956	Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. <i>Annals of Oncology</i> , 2015, 26, 1058-1068.	0.6	67
957	Prognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: A single institution analysis. <i>Oncology Letters</i> , 2015, 9, 851-856.	0.8	8
958	Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1215-1222.	0.8	7
959	Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. <i>Annals of Hematology</i> , 2015, 94, 803-812.	0.8	74
960	Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2015, 101, 585-593.	0.7	12
961	Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 569-578.	1.1	12
962	Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. <i>Cancer Epidemiology</i> , 2015, 39, 382-387.	0.8	7
963	Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. <i>BMC Cancer</i> , 2015, 15, 235.	1.1	44
964	Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). <i>Leukemia and Lymphoma</i> , 2015, 56, 921-926.	0.6	139
965	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20 <sup>+</sup> lymphoid malignancies. <i>British Journal of Haematology</i> , 2015, 170, 669-678.	1.2	80
966	Inflammation and Immunity in Cancer. , 2015, , .		1
967	Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Seminars in Hematology</i> , 2015, 52, 107-118.	1.8	16
968	A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. <i>Future Oncology</i> , 2015, 11, 1327-1342.	1.1	61
969	Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 122-129.	0.4	37
970	The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma. <i>European Journal of Cancer Care</i> , 2015, 24, 117-124.	0.7	18
971	Stage redistribution and survival among Medicare beneficiaries before and after the approval of positron emission tomography scan for non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1544-1546.	0.6	2

#	ARTICLE	IF	CITATIONS
972	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	2.9	21
973	Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant. <i>Acta Haematologica</i> , 2015, 133, 347-353.	0.7	7
974	Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2015, 94, 2043-2053.	0.8	72
975	Outcome prediction by extranodal involvement, IPI, Râ€PI, and NCCNâ€PI in the PET/CT and rituximab era: A <sc>D</sc>anishâ€ <sc>C</sc>anadian study of 443 patients with diffuseâ€large <sc>B</sc>â€cell lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 1041-1046.	2.0	71
976	Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 105-114.	0.3	6
977	Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. <i>Annals of Hematology</i> , 2015, 94, 1839-1843.	0.8	64
978	Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. <i>Oncology Research and Treatment</i> , 2015, 38, 185-192.	0.8	49
979	Influencing cancer treatment. <i>Lancet Oncology</i> , The, 2015, 16, 1591-1593.	5.1	2
980	Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. <i>Haematologica</i> , 2015, 100, 238-245.	1.7	87
981	Longâ€term followâ€up of doseâ€adjusted EPOCH plus rituximab (DAâ€EPOCHâ€R) in untreated patients with poor prognosis large Bâ€cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. <i>British Journal of Haematology</i> , 2015, 169, 188-198.	1.2	49
982	Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1020-1026.	0.6	30
983	The role of rituximab and positron emission tomography in the treatment of primary mediastinal large Bâ€cell lymphoma: experience on 74 patients. <i>Hematological Oncology</i> , 2015, 33, 145-150.	0.8	30
984	Review of Antibody-Based Immunotherapy in theâ€Treatment of Non-Hodgkin Lymphoma andâ€Patterns of Use. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 129-138.	0.2	4
985	Retrospective comparison of allogeneic vs autologous transplantation for diffuse large B-cell lymphoma with early relapse or primary induction failure. <i>Bone Marrow Transplantation</i> , 2015, 50, 134-136.	1.3	6
986	The role of <sc>FDG</sc>â€ <sc>PET</sc> imaging as a prognostic marker of outcome in primary mediastinal Bâ€cell lymphoma. <i>Cancer Medicine</i> , 2015, 4, 7-15.	1.3	18
987	Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. <i>Leukemia and Lymphoma</i> , 2015, 56, 1611-1618.	0.6	9
988	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 383-389.	0.6	7
989	The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 12-25.	0.6	18

#	ARTICLE	IF	CITATIONS
990	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 251-257.	0.8	319
991	R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 92-97.	0.2	9
992	Acute jugular vein thrombosis during rituximab administration: Review of the literature. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 165-169.	0.5	7
993	Twenty Years of Autologous Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma: A Single Portuguese Center Experience. <i>Acta Medica Portuguesa</i> , 2016, 29, 205.	0.2	1
994	Oct2, BCL6, IRF8, OCAB and PU.1 in the Assessment of Prognosis in Diffuse Large B cell Lymphoma Patients. <i>Journal of Molecular Biomarkers &amp; Diagnosis</i> , 2016, 07, .	0.4	1
995	Diffuse large B-cell lymphoma of the breast: prognostic factors and treatment outcomes. <i>OncoTargets and Therapy</i> , 2016, 9, 2069.	1.0	18
996	Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). <i>OncoTargets and Therapy</i> , 2016, 9, 3799.	1.0	5
997	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. <i>Oncotarget</i> , 2016, 7, 76934-76943.	0.8	33
998	Clinical Prognostic Models in Diffuse Large B Cell Lymphoma Patients are Still Essential in the Rituximab Era. <i>Journal of Hematology &amp; Thromboembolic Diseases</i> , 2016, 4, .	0.1	0
999	Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. <i>F1000Research</i> , 2016, 5, 1933.	0.8	8
1000	Minimally Invasive Diagnosis of Secondary Intracranial Lymphoma. <i>Case Reports in Hematology</i> , 2016, 2016, 1-4.	0.3	0
1001	Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future. <i>Pharmaceuticals</i> , 2016, 9, 28.	1.7	7
1002	Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. <i>BMC Cancer</i> , 2016, 16, 537.	1.1	11
1003	Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies. <i>Journal of Translational Medicine</i> , 2016, 14, 252.	1.8	3
1004	Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2016, 56, 100-108.	0.3	15
1006	Primary Non-Hodgkin's Lymphoma of the Vulva. <i>Medicine (United States)</i> , 2016, 95, e3041.	0.4	19
1007	Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. <i>Journal of Clinical Oncology</i> , 2016, 34, 2997-3004.	0.8	97
1008	Clinical approach to diffuse large B cell lymphoma. <i>Blood Reviews</i> , 2016, 30, 477-491.	2.8	26

#	ARTICLE	IF	CITATIONS
1009	Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. <i>Hematological Oncology</i> , 2016, 34, 184-192.	0.8	80
1010	A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 432-443.	1.2	23
1011	Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 597-616.	1.2	16
1012	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
1013	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. <i>Supportive Care in Cancer</i> , 2016, 24, 4057-4074.	1.0	21
1014	CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2016, 34, 3150-3156.	0.8	313
1015	Safety and efficacy of intrathecal rituximab in children with B-cell lymphoid CD20+ malignancies: An international retrospective study. <i>American Journal of Hematology</i> , 2016, 91, 486-491.	2.0	27
1016	Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. <i>American Journal of Hematology</i> , 2016, 91, 672-676.	2.0	27
1017	Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children. <i>British Journal of Haematology</i> , 2016, 173, 531-544.	1.2	15
1018	Adolescent and young adult non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 637-650.	1.2	30
1020	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw257.	3.0	56
1021	Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 589-597.	0.9	60
1022	Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era. <i>Nuclear Medicine Communications</i> , 2016, 37, 1095-1101.	0.5	15
1024	Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. <i>Annals of Hematology</i> , 2016, 95, 893-899.	0.8	10
1025	Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma. <i>Annals of Hematology</i> , 2016, 95, 1121-1128.	0.8	2
1026	Multidisciplinary approach for primary cardiac lymphoma associated with hemodynamic failure caused by tricuspid valve obstruction. <i>Journal of Cardiology Cases</i> , 2016, 13, 189-192.	0.2	4
1027	Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04). <i>International Journal of Hematology</i> , 2016, 103, 676-685.	0.7	6
1028	Aggressive B-Cell Lymphomas. , 2016, , 111-171.		0

#	ARTICLE	IF	CITATIONS
1029	PET/CT in Lymphomas. , 2016, , .		4
1030	Concurrent Elevations of VEGF, Osteopontin and MCP-1 Serum Levels Are Independent Predictors of Survival in Patients with Diffuse Large B-Cell Lymphoma. Acta Haematologica, 2016, 136, 52-61.	0.7	34
1031	Exploring Big Data in Hematological Malignancies: Challenges and Opportunities. Current Hematologic Malignancy Reports, 2016, 11, 271-279.	1.2	3
1032	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood, 2016, 127, 3026-3034.	0.6	168
1033	Radiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment option. Radiation Oncology, 2016, 11, 110.	1.2	28
1034	The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma. Expert Opinion on Drug Discovery, 2016, 11, 1123-1130.	2.5	5
1035	Lymphoma in Adolescents and Young Adults. Progress in Tumor Research, 2016, 43, 101-114.	0.1	9
1036	New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. Chinese Journal of Cancer, 2016, 35, 87.	4.9	15
1037	Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era. Blood Cancer Journal, 2016, 6, e477-e477.	2.8	6
1038	Epstein-Barr Virus Infection and Lymphoproliferative Disorders After Transplantation. , 2016, , 477-512.		2
1040	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. Journal of Clinical Oncology, 2016, 34, 4015-4022.	0.8	66
1041	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematology, the, 2016, 3, e388-e397.	2.2	128
1042	Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 567-576.	2.9	83
1043	A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant. Applied Radiation and Isotopes, 2016, 116, 13-21.	0.7	0
1044	Guidelines for the management of diffuse large B-cell lymphoma. British Journal of Haematology, 2016, 174, 43-56.	1.2	125
1045	Anti-CD20 antibody treatment of non-Hodgkin lymphomas. Clinical Immunology, 2016, 172, 101-104.	1.4	21
1046	State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, 1147-1162.	0.9	11
1047	Management of Relapsed Diffuse Large B-cell Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, 1195-1213.	0.9	22



#	ARTICLE	IF	CITATIONS
1048	Diffuse Large B-Cell Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, 1179-1194.	0.9	6
1049	Optimizing Outcomes in Primary Mediastinal B-cell Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, 1261-1275.	0.9	7
1050	Handbook of Lymphoma. , 2016, , .		3
1051	<scp>SPIB</scp> is a novel prognostic factor in diffuse large Bâ€cell lymphoma that mediates apoptosis via the <scp>PI</scp>3Kâ€<scp>AKT</scp> pathway. Cancer Science, 2016, 107, 1270-1280.	1.7	22
1052	Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?. Current Treatment Options in Oncology, 2016, 17, 45.	1.3	3
1053	The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. Annals of Hematology, 2016, 95, 1483-1490.	0.8	24
1054	Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum Î²2â€microglobulin level in patients with diffuse large bâ€cell lymphoma: a new prognostic model. British Journal of Haematology, 2016, 175, 290-299.	1.2	31
1055	BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era. Leukemia and Lymphoma, 2016, 57, 2199-2203.	0.6	9
1056	Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B-cell lymphoma cells. Molecular Medicine Reports, 2016, 13, 3092-3100.	1.1	9
1057	Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma. Oncology, 2016, 91, 302-310.	0.9	14
1058	Chemotherapeutic intensity and survival differences in young patients with diffuse large Bâ€cell lymphoma: a Swedish Lymphoma Registry study. British Journal of Haematology, 2016, 175, 614-622.	1.2	14
1059	Small Intestinal Cancers. , 2016, , 519-553.		0
1060	Treatment of Diffuse Large B-Cell Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2016, 56, 79-88.	0.3	52
1061	Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation. Journal of Hematopoietic Cell Transplantation, 2016, 5, 93-101.	0.1	0
1062	Evaluation of a method for calculating carboplatin dosage in DeVICÂ±ÂR therapy (combination therapy) Tj ETQq0 0 0 rgBT /Overlock 1 therapy in patients with relapsed or refractory non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology, 2016, 78, 305-312.	1.1	1
1063	Diffuse Large B-Cell Lymphoma Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 196-231.	2.3	76
1064	The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study. BMC Health Services Research, 2016, 16, 336.	0.9	7
1066	The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines. Biomarker Research, 2016, 4, 12.	2.8	29

#	ARTICLE	IF	CITATIONS
1067	Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP. <i>Medicine (United States)</i> , 2016, 95, e4893.	0.4	17
1068	Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 476-480.	2.0	25
1069	Short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results. <i>Blood Cancer Journal</i> , 2016, 6, e425-e425.	2.8	13
1070	Population pharmacokinetics of Reditux <sup>®</sup> , a biosimilar Rituximab, in diffuse large B-cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 353-359.	1.1	31
1071	Molecular targeted therapy in gynaecologic malignancies: primer for radiologists. <i>British Journal of Radiology</i> , 2016, 89, 20160086.	1.0	2
1072	Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. <i>Acta Haematologica</i> , 2016, 136, 76-84.	0.7	6
1073	Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era. <i>Leukemia and Lymphoma</i> , 2016, 57, 2619-2625.	0.6	6
1074	Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90Yttrium-ibritumomab-tiuxetan. <i>European Journal of Haematology</i> , 2016, 97, 576-582.	1.1	8
1075	CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma – a meta-analysis of randomized controlled trials. <i>Acta Oncologica</i> , 2016, 55, 77-84.	0.8	4
1076	Clinical management of HIV-associated hematologic malignancies. <i>Expert Review of Hematology</i> , 2016, 9, 361-376.	1.0	10
1077	Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy. <i>International Journal of Clinical Oncology</i> , 2016, 21, 498-505.	1.0	17
1078	Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1697-1708.	0.6	5
1079	Emerging immunotherapy in pediatric lymphoma. <i>Future Oncology</i> , 2016, 12, 257-270.	1.1	2
1080	Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment. <i>Leukemia and Lymphoma</i> , 2016, 57, 1723-1726.	0.6	4
1081	Management of Patients with MYC-Altered Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 208-217.	1.2	5
1082	High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. <i>Experimental Hematology</i> , 2016, 44, 238-246.e2.	0.2	46
1083	Evolution of radiation techniques in the treatment of mediastinal lymphoma: from 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT): a single-centre experience and review of the literature. <i>British Journal of Radiology</i> , 2016, 89, 20150409.	1.0	22
1084	Prospective Study of <sup>18</sup> F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 728-734.	2.8	41

#	ARTICLE	IF	CITATIONS
1085	Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 175-181.	0.2	27
1086	Intensity Modulated Radiation Therapy for Early-Stage Primary Gastric Diffuse Large B-Cell Lymphoma: Dosimetric Analysis, Clinical Outcome, and Quality of Life. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 712-720.	0.4	8
1087	Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy. <i>Expert Review of Hematology</i> , 2016, 9, 471-477.	1.0	18
1088	Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings. <i>Medicine (United States)</i> , 2016, 95, e2808.	0.4	16
1089	Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 4.	1.3	18
1090	Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 365-371.	1.3	43
1091	Orbital, Ocular, and Optic Nerve Tumors. , 2016, , 541-560.e6.		0
1092	Current challenges and novel treatment strategies in double hit lymphomas. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 52-64.	1.1	20
1093	Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 899-908.	0.6	7
1094	A review of monoclonal antibody therapies in lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 72-84.	2.0	41
1095	High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a <sup>177</sup> Lu-based CD22-specific radioimmunoconjugate and rituximab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 489-498.	3.3	13
1096	Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. <i>Leukemia</i> , 2016, 30, 361-372.	3.3	55
1097	Prognostic significance of PCR-based molecular staging in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 357-365.	0.6	4
1098	Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. <i>Hematological Oncology</i> , 2017, 35, 151-157.	0.8	12
1099	Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*. <i>Leukemia and Lymphoma</i> , 2017, 58, 64-69.	0.6	11
1100	Treatment approaches of hard-to-treat non-Hodgkin lymphomas. <i>Expert Review of Hematology</i> , 2017, 10, 259-273.	1.0	9
1101	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 536-543.	0.8	168
1102	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. <i>Advances in Therapy</i> , 2017, 34, 324-356.	1.3	128

#	ARTICLE	IF	CITATIONS
1103	Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 778-784.	0.8	72
1104	Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 544-551.	0.8	172
1105	Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2017, 102, e199-e202.	1.7	4
1106	Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101. <i>Leukemia Research</i> , 2017, 55, 41-48.	0.4	5
1107	How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma. <i>Blood Reviews</i> , 2017, 31, 235-249.	2.8	9
1108	Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1782-1790.	1.1	38
1110	Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma. <i>Molecular and Clinical Oncology</i> , 2017, 6, 627-633.	0.4	7
1111	Childhood Acute Lymphoblastic Leukemia. , 2017, , .		2
1112	The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 557-566.	1.5	18
1113	Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results. , 2017, , 99-122.		0
1114	Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001719.	0.5	22
1115	Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. <i>Cancer</i> , 2017, 123, 3326-3334.	2.0	60
1116	Blunt tools, burning questions: using cancer registry data to study relapsed/refractory lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1013-1015.	0.6	0
1117	LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 877-886.	2.1	19
1118	Investigation on treatment strategy, prognostic factors, and risk factors for early death in elderly Taiwanese patients with diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2017, 7, 44282.	1.6	9
1119	The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma. <i>American Journal of the Medical Sciences</i> , 2017, 353, 459-465.	0.4	13
1120	Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma. <i>Scientific Reports</i> , 2017, 7, 45682.	1.6	36
1121	Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment. <i>Annals of Hematology</i> , 2017, 96, 411-420.	0.8	19

#	ARTICLE	IF	CITATIONS
1122	CD109, a negative regulator of TGF- $\beta$ signaling, is a putative risk marker in diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2017, 105, 614-622.	0.7	22
1123	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013. <i>Leukemia and Lymphoma</i> , 2017, 58, 1805-1813.	0.6	13
1124	Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793); Tj ETQqO 006gBT /Overlock 10	0.6	10
1125	Serum level of <scp>CXCL10</scp> is associated with inflammatory prognostic biomarkers in patients with diffuse large <scp>B</scp>-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 480-486.	0.8	23
1126	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. <i>Advances in Therapy</i> , 2017, 34, 2232-2273.	1.3	407
1127	Optimization of rituximab for the treatment of <scp>DLBCL</scp>: increasing the dose for elderly male patients. <i>British Journal of Haematology</i> , 2017, 179, 410-420.	1.2	42
1128	Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. <i>Haematologica</i> , 2017, 102, 1913-1922.	1.7	52
1129	The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Scientific Reports</i> , 2017, 7, 13592.	1.6	4
1130	Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores. <i>Annals of Hematology</i> , 2017, 96, 1873-1881.	0.8	3
1131	Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2017, 7, e596-e596.	2.8	14
1132	Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use. <i>Human Gene Therapy</i> , 2017, 28, 914-925.	1.4	89
1133	Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?. <i>Expert Review of Hematology</i> , 2017, 10, 761-774.	1.0	14
1134	High-dose chemotherapy and autologous stem-cell transplantation for DLBCL in the rituximab era. <i>Lancet Oncology</i> , The, 2017, 18, 989-991.	5.1	3
1135	Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia Research</i> , 2017, 60, 89-93.	0.4	4
1136	Rituximab desensitization in three patients with severe rituximab allergy. <i>Current Problems in Cancer</i> , 2017, 41, 349-354.	1.0	5
1137	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. <i>Oncologist</i> , 2017, 22, 1415-1418.	1.9	7
1138	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2017, 377, 2545-2554.	13.9	1,390
1139	MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2017, 7, 654.	2.8	26

#	ARTICLE	IF	CITATIONS
1140	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	2.2	130
1141	Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma. <i>Medicine (United States)</i> , 2017, 96, e8494.	0.4	8
1142	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
1143	The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients. <i>BMC Cancer</i> , 2017, 17, 276.	1.1	10
1144	Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 1047-1055.	1.0	8
1145	Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP. <i>Annals of Hematology</i> , 2017, 96, 227-235.	0.8	5
1146	Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. <i>British Journal of Haematology</i> , 2017, 176, 210-221.	1.2	78
1147	R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 1105-1113.	0.6	26
1148	Non-Hodgkin Lymphoma. <i>Pediatric Oncology</i> , 2017, , 69-117.	0.5	2
1149	Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline. <i>Clinical Oncology</i> , 2017, 29, e13-e28.	0.6	14
1150	Radiation Therapy in Hematologic Malignancies. , 2017, , .		0
1151	Primary pituitary diffuse large B-cell lymphoma with somatotroph hyperplasia and acromegaly: case report. <i>Journal of Neurosurgery</i> , 2017, 126, 1725-1730.	0.9	19
1152	Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. <i>Hematological Oncology</i> , 2017, 35, 497-503.	0.8	36
1153	Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 1094-1104.	0.6	26
1154	Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study. <i>Leukemia and Lymphoma</i> , 2017, 58, 1130-1134.	0.6	11
1155	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017, 92, 161-170.	2.0	56
1156	Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial. <i>Annals of Oncology</i> , 2017, 28, 3058-3064.	0.6	11
1157	Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 284-294.	0.9	22

#	ARTICLE	IF	CITATIONS
1158	All That Wheezes Is Not Asthma: A Case of Diffuse Large B-Cell Lymphoma of the Larynx. Case Reports in Oncological Medicine, 2017, 2017, 1-4.	0.2	7
1159	<i>Pneumocystis</i> Pneumonia in Non-HIV Pregnant Women Receiving Chemotherapy for Malignant Lymphoma: Two Case Reports. Case Reports in Obstetrics and Gynecology, 2017, 2017, 1-4.	0.2	3
1160	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS ONE, 2017, 12, e0186549.	1.1	29
1161	3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis. Internal Medicine, 2017, 56, 2407-2413.	0.3	3
1162	TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP. BMC Cancer, 2017, 17, 743.	1.1	9
1163	Relevance of prognostic index with Î²2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Research, 2017, 52, 276.	0.5	11
1164	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 2017, 35, 2473-2481.	0.8	148
1165	The role of novel immunotherapies in non-Hodgkin lymphoma. Translational Cancer Research, 2017, 6, 93-103.	0.4	26
1166	Diffuse large B-cell lymphoma: 10ÃÃ1/2years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone. Oncology Letters, 2018, 15, 3602-3609.	0.8	35
1167	Prognostic significance of retention index of bone marrow on dual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma. Medicine (United States), 2018, 97, e9513.	0.4	7
1168	Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large Bâcell lymphoma upon start of Râscpc>CHOP</scpc>. Clinical Case Reports (discontinued), 2018, 6, 490-493.	0.2	1
1169	Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL). Clinica Chimica Acta, 2018, 482, 191-198.	0.5	18
1170	Rituximab-related Severe Toxicity. Annual Update in Intensive Care and Emergency Medicine, 2018, , 579-596.	0.1	2
1171	Detection of the Incidence of HBV, HCV Infection and Febrile Neutropenia Associated With CHOP With or Without Rituximab in Diffuse Large B-Cell LymphomaâTreated Patients. Hospital Pharmacy, 2018, 53, 194-197.	0.4	2
1172	Efficacy and safety of administering pediatric treatment to adolescent patients with mature Bâcell nonâHodgkin lymphoma within the Japanese Pediatric Leukemia/Lymphoma Study Group clinical trial. Pediatric Blood and Cancer, 2018, 65, e27068.	0.8	1
1173	The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and highârisk diffuse large Bâcell lymphoma. European Journal of Haematology, 2018, 101, 150-159.	1.1	6
1174	Impact of Anthracyclines on Diabetes MellitusâDevelopment in B-Cell Lymphoma Patients: A Nationwide Population-based Study. Clinical Drug Investigation, 2018, 38, 603-610.	1.1	1
1175	Malignant lymphoma in the <scpc>HIV</scpc>âpositive patient. European Journal of Haematology, 2018, 101, 119-126.	1.1	25

#	ARTICLE	IF	CITATIONS
1176	Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 28-37.	1.1	8
1177	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443.	0.8	16
1178	Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2018, 100, 644-648.	1.1	22
1179	Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. <i>Annals of Oncology</i> , 2018, 29, 1120-1129.	0.6	18
1180	Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 85-96.	3.3	13
1181	Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma. <i>Nanomedicine</i> , 2018, 13, 297-311.	1.7	4
1182	Management of chronic viral hepatitis in the hematological patient. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 227-241.	2.0	9
1184	The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. <i>Oncogene</i> , 2018, 37, 1830-1844.	2.6	69
1185	HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma. <i>Cell Death and Disease</i> , 2018, 9, 61.	2.7	14
1186	Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition. <i>Haematologica</i> , 2018, 103, 466-476.	1.7	23
1187	Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 135-141.	0.6	1
1188	Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration – a retrospective study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1871-1877.	0.6	13
1189	Monoclonal Antibodies Targeting Hematological Malignancies. , 2018, , 79-116.		0
1190	T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX). <i>Medicine (United States)</i> , 2018, 97, e0199.	0.4	5
1191	Immunology of the Lymphomas. , 2018, , 827-852.		1
1192	Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. <i>Immunotherapy</i> , 2018, 10, 699-711.	1.0	7
1193	Incidence of interstitial pneumonitis in non-Hodgkin lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab. <i>Annals of Hematology</i> , 2018, 97, 141-147.	0.8	19
1194	Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients With Diffuse Large B-cell Lymphoma (DLBCL) in Long-term Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e27-e34.	0.2	10



#	ARTICLE	IF	CITATIONS
1195	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
1196	Aptamers as potential therapeutic agents for ovarian cancer. <i>Biochimie</i> , 2018, 145, 34-44.	1.3	17
1197	Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score. <i>Medical Oncology</i> , 2018, 35, 5.	1.2	33
1198	New developments in immunotherapy for pediatric solid tumors. <i>Current Opinion in Pediatrics</i> , 2018, 30, 30-39.	1.0	16
1199	Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China. <i>Chinese Medical Journal</i> , 2018, 131, 1767-1775.	0.9	9
1200	Novel markers for determining risk and evaluation of minimal residual disease in diffuse large B-cell lymphoma. <i>Annals of Lymphoma</i> , 0, 1, 1-1.	4.5	0
1201	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patientâ€œLevel Analysis of Multiple Randomized Trials (SEAL). <i>Journal of Clinical Oncology</i> , 2018, 36, 2593-2602.	0.8	59
1202	Early-Stage Follicular Lymphoma: What Is the Preferred Treatment Strategy?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2904-2906.	0.8	7
1203	Reply to H. Tilly et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 923-925.	0.8	0
1204	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
1205	Coexisting B- Cell Lymphoma and Benign Mesenchymal Phosphaturic Tumor: Debut as Acute Renal Failure Associated with Hypercalcemia and Hypophosphatemia. <i>Journal of Clinical Case Reports</i> , 2018, 08, .	0.0	0
1206	Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 32383-32399.	0.8	9
1207	Trends in Survival of Patients with Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database. <i>Disease Markers</i> , 2018, 2018, 1-7.	0.6	5
1208	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. <i>Blood Cancer Journal</i> , 2018, 8, 108.	2.8	32
1209	Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites. <i>Current Oncology</i> , 2018, 25, 300-306.	0.9	7
1210	Lymphoma in Adolescents and Young Adults. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 285-300.	1.0	7
1211	Treatment of malignant primary cardiac lymphoma with tumor resection using minimally invasive cardiac surgery. <i>Journal of Cardiothoracic Surgery</i> , 2018, 13, 97.	0.4	8
1212	Relative survival of patients with lymphoma in Queensland according to histological subtype. <i>Medical Journal of Australia</i> , 2018, 209, 166-172.	0.8	3

#	ARTICLE	IF	CITATIONS
1213	Light therapy as a treatment of cancer-related fatigue in (non-)Hodgkin lymphoma survivors (SPARKLE) Tj ETQq0 0 0 1.1rgBT /Overlock 10 T	1.1	20
1214	Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why. Journal of Hematology and Oncology, 2018, 11, 75.	6.9	18
1215	Colorectal Lymphoma: A Review. Clinics in Colon and Rectal Surgery, 2018, 31, 309-316.	0.5	19
1216	New developments in immunotherapy for lymphoma. Cancer Biology and Medicine, 2018, 15, 189.	1.4	24
1217	Recent Advances in Diffuse Large B Cell Lymphoma. , 2018, , .		2
1218	Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients. Current Treatment Options in Oncology, 2018, 19, 50.	1.3	8
1219	Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma. American Journal of Hematology, 2018, 93, 1020-1028.	2.0	23
1220	Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. Expert Opinion on Emerging Drugs, 2018, 23, 111-122.	1.0	14
1221	Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Medicine, 2018, 7, 2868-2875.	1.3	19
1222	Non-Hodgkin's Lymphoma. , 2018, , 757-768.		0
1223	Primary CNS lymphoma in HIV infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 152, 177-186.	1.0	62
1224	Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment. Clinical Journal of Oncology Nursing, 2018, 22, 407-414.	0.3	5
1225	Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 679-686.	0.2	3
1226	Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. , 2018, , 951-973.		0
1227	Successful role of radiation therapy: Account for every single gray and make every single gray count. Best Practice and Research in Clinical Haematology, 2018, 31, 217-232.	0.7	1
1228	Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leukemia Research, 2018, 71, 100-105.	0.4	13
1229	Malignant Lymphomas in Childhood. , 2018, , 1330-1342.e5.		2
1230	Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors. Cancers, 2018, 10, 200.	1.7	36

#	ARTICLE	IF	CITATIONS
1231	CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. <i>Molecular Therapy</i> , 2018, 26, 1906-1920.	3.7	38
1232	Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 163.	1.3	238
1233	Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 45.	1.3	5
1234	Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab. <i>Annals of Hematology</i> , 2018, 97, 2253-2255.	0.8	5
1235	A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma. <i>Tumori</i> , 2018, 104, 292-299.	0.6	14
1236	NHL in adolescents and young adults: A unique population. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27073.	0.8	19
1237	Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 297.	0.8	36
1238	Anti-CD20 monoclonal antibodies: reviewing a revolution. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2820-2841.	1.4	68
1239	Utility of Left Ventricular Ejection Fraction Measurements Before the Administration of Doxorubicin-Based Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2018, 2, 277-285.	1.2	4
1240	Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1709-1718.	2.0	7
1241	Non-Hodgkin lymphoma. <i>BMJ: British Medical Journal</i> , 2018, 362, k3204.	2.4	60
1242	Surrogate end points in lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1622-1623.	0.6	5
1243	R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial. <i>Hematological Oncology</i> , 2018, 36, 638-644.	0.8	23
1244	Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. <i>Annals of Oncology</i> , 2018, 29, 1822-1827.	0.6	61
1245	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2018, 5, e563-e598.	2.2	97
1246	Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 65-79.	3.3	55
1247	The impact of SOCS1 mutations in diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2019, 187, 627-637.	1.2	15
1248	Rituximab in primary central nervous system lymphoma—A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	0.8	54

#	ARTICLE	IF	CITATIONS
1249	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. <i>Blood Advances</i> , 2019, 3, 1661-1669.	2.5	21
1251	A phase III randomized controlled trial of radiation dose optimization in non-Hodgkin lymphoma diffuse large B-cell lymphoma (DOBL study): Study protocol and design. <i>Cancer Reports</i> , 2019, 2, e1161.	0.6	1
1252	Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study. <i>Archives of Medical Science</i> , 2021, 17, 920-927.	0.4	0
1253	A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage II diffuse large B-cell lymphoma (KROC 17-02). <i>Journal of Radiation Research</i> , 2019, 60, 677-684.	0.8	3
1254	Microcosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi. <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	3
1255	Optimizing treatment combination for lymphoma using an optimization heuristic. <i>Mathematical Biosciences</i> , 2019, 315, 108227.	0.9	1
1256	CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 360-367.	0.8	21
1257	Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 207-218.	1.2	17
1258	Rituximab biosimilar RTX83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. <i>Leukemia and Lymphoma</i> , 2019, 60, 3375-3385.	0.6	22
1259	Cost burden of diffuse large B-cell lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 645-661.	0.7	14
1260	Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. <i>Cancer Medicine</i> , 2019, 8, 7174-7185.	1.3	13
1261	Mature NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies. <i>British Journal of Haematology</i> , 2019, 185, 1071-1085.	1.2	27
1263	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37
1265	Rituximab biosimilars for lymphoma in Europe. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1045-1056.	1.4	13
1266	NK Cells in the Treatment of Hematological Malignancies. <i>Journal of Clinical Medicine</i> , 2019, 8, 1557.	1.0	39
1268	Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 1053-1062.	1.0	14
1269	A Case of Double Expresser Diffuse Large B Cell Lymphoma Treated with R-CODOX-M/R-IVAC. <i>Case Reports in Oncology</i> , 2019, 12, 595-602.	0.3	2
1270	Incidence and Risk Factors for Developing Herpes Zoster Among a Cohort of Patients Diagnosed With Lymphoma at a Community Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e153-e158.	0.2	3

#	ARTICLE	IF	CITATIONS
1271	Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABCâ€‘subtype diffuse large Bâ€‘cell lymphoma. <i>Journal of Pathology</i> , 2019, 248, 142-154.	2.1	8
1273	Case of Gastric Diffuse Large B-Cell Lymphoma. <i>Case Reports in Oncology</i> , 2019, 12, 39-46.	0.3	5
1274	Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 572-580.	0.6	17
1275	A populationâ€‘based multistate model for diffuse large Bâ€‘cell lymphomaâ€‘specific mortality in older patients. <i>Cancer</i> , 2019, 125, 1837-1847.	2.0	12
1276	<i>Hematologic Cancers.</i> , 2019, , 397-429.		0
1277	Genetic alterations and their clinical implications in DLBCL. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 634-652.	12.5	136
1278	Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large Bâ€‘cell lymphoma receiving rituximabâ€‘chemotherapy combinations. <i>British Journal of Haematology</i> , 2019, 187, 73-81.	1.2	19
1279	Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial. <i>Lancet Haematology</i> ,the, 2019, 6, e328-e337.	2.2	31
1280	Novel Treatments for Lymphoma. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2019, 49, 903-915.	0.5	20
1281	Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes. <i>Leukemia</i> , 2019, 33, 2662-2672.	3.3	24
1282	<i>Principles of Immunotherapy.</i> , 2019, , 295-304.		0
1283	EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions. <i>Journal of Cancer</i> , 2019, 10, 2006-2017.	1.2	17
1284	Rituximab in the treatment of childhood mature Bâ€‘cell lymphoma: â€‘Where do we go from hereâ€‘. <i>British Journal of Haematology</i> , 2019, 185, 1017-1020.	1.2	5
1285	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e026644.	0.8	27
1286	Novel Mechanism Regulates c-Myc Expression in Diffuse Large B-cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2019, 112, 7-9.	3.0	3
1287	Intravenous but not intrathecal central nervous systemâ€‘directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2019, 115, 27-36.	1.3	10
1288	&lt;p&gt;Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study&lt;/p&gt;. <i>Clinical Epidemiology</i> , 2019, Volume 11, 207-216.	1.5	14
1289	Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma. <i>JAMA Network Open</i> , 2019, 2, e192093.	2.8	7

#	ARTICLE	IF	CITATIONS
1290	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 48.	2.8	24
1291	Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma. , 2019, , 167-183.		1
1292	Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkinâ€™s Lymphoma. <i>Pharmaceutical Research</i> , 2019, 36, 82.	1.7	5
1293	Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 407-418.	1.0	4
1294	&lt;p&gt;How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin&rsquo;s lymphomas&lt;/p&gt;. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 71-84.	0.7	33
1295	Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells. <i>Cancers</i> , 2019, 11, 291.	1.7	13
1296	Prognostic value of some inflammatory markers in patients with lymphoma. <i>Bioscience Reports</i> , 2019, 39, .	1.1	10
1297	Chimeric Antigen Receptorâ€™ Engineered T Cell Therapy in Lymphoma. <i>Current Oncology Reports</i> , 2019, 21, 38.	1.8	20
1298	Analysis of inline-filter blockage with trastuzumab formulation using scanning-electron microscopy. <i>Biomedicine and Pharmacotherapy</i> , 2019, 112, 108711.	2.5	1
1299	Primary testicular lymphoma: A SEER analysis of 1,169;1/2cases. <i>Oncology Letters</i> , 2019, 17, 3113-3124.	0.8	20
1300	Clinical features and outcomes of pulmonary lymphoma: A single center experience of 180 cases. <i>Lung Cancer</i> , 2019, 132, 39-44.	0.9	16
1301	Ability of <sup>18</sup> F-FDG PET/CT Radiomic Features to Distinguish Breast Carcinoma from Breast Lymphoma. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-9.	0.4	33
1302	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	0.8	266
1303	Chemotherapy and Beyond. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 289-309.	1.9	34
1304	Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 96-101.	0.4	11
1305	De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1267-1269.	0.8	3
1306	Serum level of soluble interleukinâ€™2 receptor is positively correlated with metabolic tumor volume on <sup>18</sup> Fâ€™FDG PET/CT in newly diagnosed patients with diffuse large Bâ€™cell lymphoma. <i>Cancer Medicine</i> , 2019, 8, 953-962.	1.3	10
1307	Complications and outcomes in diffuse large Bâ€™cell lymphoma with gastric lesions treated with Râ€™CHOP. <i>Cancer Medicine</i> , 2019, 8, 982-989.	1.3	15

#	ARTICLE	IF	CITATIONS
1308	Pediatric non-Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand. <i>Pediatrics International</i> , 2019, 61, 49-57.	0.2	4
1309	Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. <i>Future Oncology</i> , 2019, 15, 1021-1034.	1.1	23
1310	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. <i>The Cochrane Library</i> , 2019, , .	1.5	2
1311	Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer. <i>Clinical Epigenetics</i> , 2019, 11, 192.	1.8	1
1312	Molecular biomarkers of DNA damage in diffuse large-cell lymphoma—a review. <i>Journal of Laboratory and Precision Medicine</i> , 0, 4, 5-5.	1.1	5
1313	Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 571-573.	0.3	3
1314	Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia With High Tumor Burden Treated With BFM95-based Protocol Combining Rituximab: A Report From Shanghai, China. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 170-174.	0.3	2
1315	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2019, 394, 2271-2281.	6.3	155
1316	Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?. <i>HemaSphere</i> , 2019, 3, e284.	1.2	9
1317	A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF- $\kappa$ B-double-targeting to molecularly assess therapy response. <i>International Journal of Hematologic Oncology</i> , 2019, 8, IJH20.	0.7	7
1318	A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 904-911.	0.6	8
1319	Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 149-156.	0.2	2
1320	Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 401-411.	0.8	41
1321	Biodistribution and Dosimetry of Indigenously Produced <sup>131</sup> I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods. <i>Journal of Nuclear Medicine Technology</i> , 2019, 47, 292-299.	0.4	0
1322	Efficacy of the GMALL-BALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin lymphomas with or without CNS involvement. <i>European Journal of Haematology</i> , 2019, 102, 241-250.	1.1	7
1323	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4
1324	Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 1-16.	2.0	9
1325	Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells. <i>Cancer Science</i> , 2019, 110, 269-278.	1.7	41

#	ARTICLE	IF	CITATIONS
1326	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e51-e61.	0.2	7
1327	Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. <i>Leukemia and Lymphoma</i> , 2019, 60, 894-903.	0.6	18
1328	The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. <i>Future Oncology</i> , 2019, 15, 305-317.	1.1	5
1329	Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1042-1052.	0.5	4
1330	Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 393-399.	1.3	29
1331	Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100502.	1.0	12
1332	Special Issues in Pregnancy. , 2020, , 882-893.e3.		0
1333	Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma – Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007–2015. <i>Journal of Geriatric Oncology</i> , 2020, 11, 41-54.	0.5	7
1334	Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution. <i>Leukemia and Lymphoma</i> , 2020, 61, 575-581.	0.6	3
1335	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	2.0	18
1336	OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma. <i>Cancer Medicine</i> , 2020, 9, 1790-1797.	1.3	10
1338	Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia and Lymphoma</i> , 2020, 61, 1119-1125.	0.6	5
1339	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020, 104, 400-408.	1.1	3
1340	Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2020, 88, 106286.	0.4	1
1341	New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta <sub>2</sub> microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). <i>British Journal of Haematology</i> , 2020, 188, 888-897.	1.2	40
1342	Survival benefit associated with treating follicular lymphoma in patients 80 years or older. <i>Journal of Geriatric Oncology</i> , 2020, 11, 55-61.	0.5	2
1343	Clinicopathologic features and prognostic significance of CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. <i>Biomarkers</i> , 2020, 25, 69-75.	0.9	14
1345	Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. <i>PLoS ONE</i> , 2020, 15, e0238807.	1.1	6



#	ARTICLE	IF	CITATIONS
1346	Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation. <i>Immuno-Oncology Technology</i> , 2020, 7, 15-22.	0.2	3
1347	Positron Emission Tomography-â€Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	0.8	75
1349	&lt;p&gt;Characteristics and Management of &lt;em&gt;TP53&lt;/em&gt;-Mutated Diffuse Large B-Cell Lymphoma Patients&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 11515-11522.	0.9	8
1350	Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients. <i>Translational Cancer Research</i> , 2020, 9, 5139-5146.	0.4	2
1351	miRNA signature associated with Râ€CHOP refractoriness in patients diagnosed with diffuse large B cell lymphoma. <i>Non-coding RNA Research</i> , 2020, 5, 185-190.	2.4	4
1352	Caution in Expanding the Use of Abbreviated R-CHOP to Poor-Risk Limited-Stage DLBCL. <i>Journal of Clinical Oncology</i> , 2020, 38, 4221-4222.	0.8	2
1353	Hematopoietic stem cell transplantation and chimeric antigen receptor TÂcell for relapsed or refractory diffuse large B-cell lymphoma. <i>Immunotherapy</i> , 2020, 12, 997-1006.	1.0	17
1354	Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy. <i>BMC Cancer</i> , 2020, 20, 742.	1.1	4
1355	Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2020, 99, 2859-2868.	0.8	32
1356	Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. <i>Annals of Hematology</i> , 2020, 99, 2577-2586.	0.8	1
1357	Treatment of Early (Limited)-Stage DLBCL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S34-S36.	0.2	1
1358	Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1684-1690.	0.5	2
1359	Network meta-analysis of targetedÂtherapies for diffuse large B cell lymphoma. <i>BMC Cancer</i> , 2020, 20, 1218.	1.1	3
1360	Survival and consolidative radiotherapy in patients living with HIV and treated for diffuse large B-cell lymphoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 956-960.	0.3	2
1361	A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients. <i>Haematologica</i> , 2020, 105, 2667-2670.	1.7	20
1362	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1345-1352.	1.9	6
1363	Gastric lymphoma complicated by phlegmonous gastritis and Guillainâ€BarrÃ© syndrome. <i>Medicine (United States)</i> , 2020, 99, e20030.	0.4	4
1364	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. <i>Blood</i> , 2020, 135, 2041-2048.	0.6	158

#	ARTICLE	IF	CITATIONS
1365	The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL). <i>Annals of Hematology</i> , 2020, 99, 1583-1594.	0.8	0
1366	Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B-cell lymphoma receiving immunochemotherapy. <i>European Journal of Haematology</i> , 2020, 105, 399-407.	1.1	8
1367	Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 831-839.	1.4	9
1368	Impact of HIV infection on consolidative radiotherapy for non-Hodgkin diffuse large B-cell lymphoma. <i>Radiation Oncology</i> , 2020, 15, 153.	1.2	1
1369	Recent survival trends in diffuse large B-cell lymphoma—“Have we made any progress beyond rituximab?”. <i>Cancer Medicine</i> , 2020, 9, 5519-5525.	1.3	15
1370	Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study. <i>International Journal of Hematology</i> , 2020, 112, 369-376.	0.7	1
1371	Adult primary testicular lymphoma: clinical features and survival in a series of patients treated at a high-volume institution in China. <i>BMC Cancer</i> , 2020, 20, 220.	1.1	20
1372	Outcome and determinants of failure to complete primary CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 740-748.	2.0	10
1373	Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1222-1230.	0.6	10
1374	Advances in targeted therapy for malignant lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 15.	7.1	66
1375	A retrospective study on prephase therapy prior to definitive multiagent chemotherapy in aggressive lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 1508-1511.	0.6	4
1376	Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications. <i>International Journal of Cancer</i> , 2020, 147, 1979-1986.	2.3	6
1377	The Many Facets of CD38 in Lymphoma: From Tumor Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy. <i>Cells</i> , 2020, 9, 802.	1.8	23
1378	Real world evidence on rituximab utilization: Combining administrative and hospital-pharmacy data. <i>PLoS ONE</i> , 2020, 15, e0229973.	1.1	5
1379	Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. <i>Cytokine</i> , 2020, 129, 155048.	1.4	8
1380	Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 195-205.	1.0	24
1381	Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen. <i>Leukemia and Lymphoma</i> , 2020, 61, 2638-2644.	0.6	2
1382	Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma. <i>Annals of Hematology</i> , 2020, 99, 1823-1831.	0.8	14

#	ARTICLE	IF	CITATIONS
1383	The Role of Rituximab in Primary Central Nervous System Lymphoma. <i>Current Oncology Reports</i> , 2020, 22, 78.	1.8	6
1384	Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. <i>British Journal of Haematology</i> , 2020, 189, 1119-1126.	1.2	69
1385	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. <i>Leukemia</i> , 2020, 34, 2184-2197.	3.3	45
1386	Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century – a Swedish lymphoma register study. <i>British Journal of Haematology</i> , 2020, 189, 1083-1092.	1.2	24
1387	Significance of bulky mass and residual tumor – Treated with or without consolidative radiotherapy – To the risk of relapse in DLBCL patients. <i>Cancer Medicine</i> , 2020, 9, 1966-1977.	1.3	17
1388	Hypercalcemia at diagnosis of diffuse large B-cell lymphoma is not uncommon and is associated with high-risk features and a short diagnosis-to-treatment interval. <i>Hematological Oncology</i> , 2020, 38, 326-333.	0.8	4
1390	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 909-933.	0.4	67
1391	EHA evaluation of the ESMO – Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	2.0	10
1392	The clinical outcomes of rituximab biosimilar CT-P10 (Truxima <sup>®</sup> ) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience. <i>Leukemia and Lymphoma</i> , 2020, 61, 1575-1583.	0.6	17
1393	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	2.5	29
1394	An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy. <i>Journal of Translational Medicine</i> , 2020, 18, 144.	1.8	10
1395	Chimeric antigen receptor T-cell therapy toxicities. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2414-2424.	1.1	19
1396	Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 718-729.	1.7	75
1397	Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 55.e1-55.e7.	0.6	7
1398	Pretreatment lymphocyte-to-monocyte ratios predict AIDS-related diffuse large B-cell lymphoma overall survival. <i>Journal of Medical Virology</i> , 2021, 93, 3907-3914.	2.5	7
1399	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	0.6	48
1400	Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e373-e380.	0.2	6
1401	R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience. <i>Annals of Hematology</i> , 2021, 100, 1517-1524.	0.8	5

#	ARTICLE	IF	CITATIONS
1402	A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands. <i>Leukemia and Lymphoma</i> , 2021, 62, 549-559.	0.6	5
1403	Investigational drugs for the treatment of diffuse large B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 25-38.	1.9	24
1404	Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 220-230.	0.4	7
1405	Leptomeningeal relapse in primary cutaneous DLBCL : Implications for a prophylactic CNS therapy. <i>Cancer Reports</i> , 2021, 4, e1295.	0.6	3
1406	VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma. <i>European Journal of Haematology</i> , 2021, 106, 100-104.	1.1	4
1407	Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2021, 17, 411-422.	1.1	7
1408	Clinico-Pathologic Profile and Treatment Outcomes of Patients with Diffuse Large B Cell Lymphoma Based on Cell of Origin Classification. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 226-231.	0.3	2
1409	A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 137, 600-609.	0.6	79
1410	Anti-CD20 treatment for B-cell malignancies: current status and future directions. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 161-181.	1.4	24
1411	A comparison of R-EPOCH and R-CHOP as a first-line regimen in <i>de novo</i> DLBCL patients with high Ki-67 expression in a single institution. <i>Oncotarget</i> , 0, 7, 41242-41250.	0.8	11
1412	External Beam Radiotherapy for Thyroid Malignancy. , 2021, , 452-460.e2.		0
1414	Radiotherapy for early and advanced stages Follicular Lymphoma. <i>Clinics</i> , 2021, 76, e2059.	0.6	0
1415	Applying probability calibration to ensemble methods to predict 2-year mortality in patients with DLBCL. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 14.	1.5	5
1416	Pharmacoeconomic Analysis of R-DA-EPOCH and R-mNHL-BFM-90 Combination Immunochemotherapy in Patients with Prognostically Unfavorable Diffuse Large B-Cell Lymphoma within Randomized Multi-Center Clinical Trial DLBCL-2015. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 321-332.	0.1	3
1417	Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China. <i>Cancer Communications</i> , 2021, 41, 229-239.	3.7	15
1418	Expression of N <sup>6</sup> -methyladenosine (m <sup>6</sup> A) regulators correlates with immune microenvironment characteristics and predicts prognosis in diffuse large cell lymphoma (DLBCL). <i>Bioengineered</i> , 2021, 12, 6115-6133.	1.4	9
1419	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198957.	1.1	9
1420	Primary Breast Diffuse Large B-Cell Lymphoma in a 42-Year-Old Female: A Case Report and Review of Literature. <i>Journal of Medical Cases</i> , 2021, 12, 181-185.	0.4	4

#	ARTICLE	IF	CITATIONS
1421	Magen und Duodenum. , 2021, , 113-164.		0
1422	Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy. Scientific Reports, 2021, 11, 785.	1.6	5
1423	Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a Tj ETQq0 0 0 rgBT /Overlock 10 T Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 405-416.	0.7	6
1424	A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Blood Advances, 2021, 5, 984-993.	2.5	9
1425	Clinicopathological characteristics and prognostic factors of primary pulmonary lymphoma. Journal of Thoracic Disease, 2021, 13, 1106-1117.	0.6	10
1426	Emerging Role of Consolidative Radiotherapy After Complete Remission Following R-CHOP Immunochemotherapy in Stage III&IV Diffuse Large B-Cell Lymphoma: A Single Institutional and Case-Matched Control Study. Frontiers in Oncology, 2021, 11, 578865.	1.3	1
1427	Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma. Current Hematologic Malignancy Reports, 2021, 16, 72-81.	1.2	7
1428	Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 162-169.	0.2	3
1429	Differential diagnostic ability of 18F-FDG PET/CT radiomics features between renal cell carcinoma and renal lymphoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2021, 65, 72-78.	0.4	12
1430	Outcomes after intensive care unit admission in newly diagnosed diffuse large B&cell lymphoma patients: A real&life study. European Journal of Haematology, 2021, 106, 788-799.	1.1	4
1431	Relapsed/Refractory International Prognostic Index (R<sc>R&PI</sc>): An international prognostic calculator for relapsed/refractory diffuse large B&cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	2.0	8
1432	Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial. Advances in Therapy, 2021, 38, 1889-1903.	1.3	9
1433	The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?. Leukemia Research, 2021, 102, 106521.	0.4	3
1434	Interim and end&of&treatment PET&CT suffers from high false&positive rates in DLBCL: Biopsy is needed prior to treatment decisions. Cancer Medicine, 2021, 10, 3035-3044.	1.3	5
1435	Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 246-256.e2.	0.2	2
1436	Dimethyl fumarate induces ferroptosis and impairs NF- $\kappa$ B/STAT3 signaling in DLBCL. Blood, 2021, 138, 871-884.	0.6	71
1437	Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*. Leukemia and Lymphoma, 2021, 62, 2094-2106.	0.6	7
1438	Novel model predicts prognosis for patients with diffuse large B-cell lymphoma in first relapse after initial R-CHOP therapy: a single-institution study in China. Journal of International Medical Research, 2021, 49, 030006052110029.	0.4	1

#	ARTICLE	IF	CITATIONS
1439	FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL&gt;60 trials. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3550-3559.	3.3	21
1440	Realâ€world evidence of tisagenlecleucel for the treatment of relapsed or refractory large Bâ€cell lymphoma. Cancer Medicine, 2021, 10, 3214-3223.	1.3	73
1441	Antibody Therapies for Large B-Cell Lymphoma. Biologics: Targets and Therapy, 2021, Volume 15, 153-174.	3.0	0
1442	IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL. BMC Cancer, 2021, 21, 603.	1.1	7
1443	Prognostic Role of Interim 18-Fluorodeoxyglucose-PET in Diffuse Large B Cell Lymphoma: Experience from a Tertiary Care Centre in North India. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 211-222.	0.3	0
1444	Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 711-719.	0.2	2
1445	High-dose Chemotherapy Combined with Autologous Hematopoietic Stem Cell Transplantation as Frontline Therapy for Intermediate/High-risk Diffuse Large B Cell Lymphoma. Current Medical Science, 2021, 41, 465-473.	0.7	1
1446	Primary colonic lymphoma: report of two cases and a literature review. Journal of International Medical Research, 2021, 49, 0300060521110170.	0.4	3
1447	Epidemiological features of primary breast lymphoma patients and development of a nomogram to predict survival. Breast, 2021, 57, 49-61.	0.9	10
1448	The â€Magic Bulletâ€Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells, 2021, 10, 1511.	1.8	3
1449	Immunotherapy in the treatment of lymphoma. World Journal of Stem Cells, 2021, 13, 503-520.	1.3	3
1450	Angiogenesisâ€™ related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients. Tumor Biology, 2021, 43, 129-140.	0.8	3
1451	R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement. Journal of Cancer Research and Clinical Oncology, 2022, 148, 205-214.	1.2	5
1452	Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4years. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	0
1453	Treating Early-Stage DLBCL on the FLYER: What Lesson for Radiation Therapy?. Frontiers in Oncology, 2021, 11, 686223.	1.3	1
1454	Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma. Clinical and Experimental Medicine, 2022, 22, 173-181.	1.9	4
1455	Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood, 2021, 138, 1110-1119.	0.6	30
1456	Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 861-872.	0.2	13

#	ARTICLE	IF	CITATIONS
1457	Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma – first analysis of toxicity and efficacy signals. <i>Leukemia and Lymphoma</i> , 2021, , 1-9.	0.6	1
1458	Blastic Plasmacytoid Dendritic Cell Neoplasm without Cutaneous Manifestation: A Case Report. <i>American Journal of Case Reports</i> , 2021, 22, e932887.	0.3	0
1459	Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. <i>British Journal of Haematology</i> , 2021, 195, 561-570.	1.2	7
1461	Current progress and future perspectives of research on intravascular large B-cell lymphoma. <i>Cancer Science</i> , 2021, 112, 3953-3961.	1.7	14
1462	Probability calibration-based prediction of recurrence rate in patients with diffuse large B-cell lymphoma. <i>BioData Mining</i> , 2021, 14, 38.	2.2	3
1463	The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatin (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial. <i>HemaSphere</i> , 2021, 5, e636.	1.2	7
1464	Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study. <i>Nutrients</i> , 2021, 13, 3243.	1.7	7
1465	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. <i>The Cochrane Library</i> , 2021, 2021, CD013365.	1.5	18
1466	Comparative assessment of efficacy and toxicity of R-DA-EPOCH and R-mNHL-BFM-90 induction courses in the treatment of patients with diffuse large B-cell lymphoma with poor prognostic factors in a randomized multicenter clinical trial – DLBCL-2015. <i>Oncogematologiya</i> , 2021, 16, 86-94.	0.1	2
1467	The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy. <i>Medical Oncology</i> , 2021, 38, 124.	1.2	6
1468	The beneficial effect of Escalated R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study. <i>Cancer Medicine</i> , 2021, 10, 7650-7664.	1.3	2
1469	Ká¼T QUÁ“ HÃ“A TRÁ“Š PHÃC Ä“’ R-CHOP Bá»†NH U LYMPHO KHÃ”NG HODGKIN Tá¼ BÃ“O B Lá»ŠN LAN Tá»ŽA. <i>Y Hoc Viet Nam</i> , 505, .	0.0	0
1470	Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 638757.	1.3	6
1471	Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B cell lymphoma. <i>Leukemia Research</i> , 2021, 110, 106664.	0.4	5
1472	The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era. <i>Leukemia Research</i> , 2021, 110, 106715.	0.4	6
1474	Monoclonal Antibodies in the Treatment of Malignant Lymphomas. <i>Advances in Experimental Medicine and Biology</i> , 2008, 610, 155-176.	0.8	3
1475	Non-Hodgkin’s Lymphoma. , 2010, , 583-592.		2
1476	Diffuse Large B-Cell Lymphomas in Older Adults. , 2020, , 583-612.		1

#	ARTICLE	IF	CITATIONS
1477	Hodgkin and Non-Hodgkin Lymphomas During Pregnancy. , 2008, 178, 111-121.		8
1478	Primary Intraocular Lymphoma. , 2016, , 1467-1485.		4
1479	Primary Mediastinal Large B-Cell Lymphoma. , 2014, , 195-206.		1
1480	Monoclonal antibody therapy. , 2009, , 303-406.		4
1481	EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly. , 2012, , 83-98.		1
1482	Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. Annals of Nuclear Medicine, 2021, 35, 24-30.	1.2	14
1483	Non-Hodgkin's Lymphoma. , 2008, , 2371-2404.		3
1485	Non-Hodgkin Lymphoma. , 2014, , 2033-2059.e8.		1
1487	A real-world study of first-line therapy in 280 consecutive Swedish patients >=80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (>=85 years) do well on curative intended therapy. Leukemia and Lymphoma, 2020, 61, 2136-2144.	0.6	5
1488	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
1489	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology American Society of Hematology Education Program, 2012, 2012, 402-9.	0.9	44
1490	Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology American Society of Hematology Education Program, 2012, 2012, 402-409.	0.9	48
1491	Primary Pulmonary Diffuse Large B Cell Non-Hodgkin's Lymphoma: A Case Report and Literature Review. American Journal of Case Reports, 2017, 18, 286-290.	0.3	15
1492	ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. F1000Research, 2020, 9, 941.	0.8	3
1493	KMWin " A Convenient Tool for Graphical Presentation of Results from Kaplan-Meier Survival Time Analysis. PLoS ONE, 2012, 7, e38960.	1.1	21
1494	Lymphotoxin Alpha (LTA) Polymorphism Is Associated with Prognosis of Non-Hodgkin's Lymphoma in a Chinese Population. PLoS ONE, 2013, 8, e66411.	1.1	6
1495	A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma. PLoS ONE, 2017, 12, e0183969.	1.1	12
1496	Prognostic Utility of Transforming Growth Factor Beta-1 in Diffuse Large Cell Non-Hodgkin Lymphoma. Journal of Hematology (Brossard, Quebec), 2015, 4, 131-136.	0.4	3



#	ARTICLE	IF	CITATIONS
1497	Myeloablative Anti-CD20 Radioimmunotherapy +/- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival. <i>Oncotarget</i> , 2013, 4, 899-910.	0.8	19
1498	The role of surgical intervention in primary colorectal lymphoma: A SEER population-based analysis. <i>Oncotarget</i> , 2016, 7, 72263-72275.	0.8	19
1499	A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. <i>Oncotarget</i> , 2017, 8, 47007-47019.	0.8	26
1500	<i>ABCG2</i> and <i>NCF4</i> polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Oncotarget</i> , 2017, 8, 58292-58303.	0.8	18
1501	Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients. <i>Oncotarget</i> , 2017, 8, 73168-73176.	0.8	9
1502	Clinical and histological features of primary testicular diffuse large B-cell lymphoma: a single center experience in China. <i>Oncotarget</i> , 2017, 8, 112384-112389.	0.8	10
1503	Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. <i>Oncotarget</i> , 2014, 5, 4050-4059.	0.8	23
1504	Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 76740-76748.	0.8	34
1505	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. <i>Oncotarget</i> , 2017, 8, 113895-113909.	0.8	15
1506	Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014. <i>Oncotarget</i> , 2018, 9, 3956-3967.	0.8	24
1507	Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. <i>Oncotarget</i> , 2018, 9, 4020-4033.	0.8	40
1508	Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2019, 10, 3285-3293.	0.8	3
1509	<i>SOCS1</i> Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Oncotarget</i> , 2013, 4, 35-47.	0.8	44
1510	Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. <i>Oncotarget</i> , 2016, 7, 33331-33339.	0.8	6
1511	Turning to Computer-aided Drug Design in the Treatment of Diffuse Large B-cell Lymphoma: Has it been Helpful?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 1325-1339.	0.9	2
1512	A Systematic Review of Economic Analyses Studying Rituximab in R-CHOP Therapy in Patients with Non-Hodgkin Lymphoma. <i>The Open Cancer Immunology Journal</i> , 2009, 2, 1-9.	0.2	3
1513	Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study. <i>Anticancer Research</i> , 2017, 37, 2655-2662.	0.5	7
1514	Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 1181-1184.	0.5	2

#	ARTICLE	IF	CITATIONS
1515	Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 1229-1236.	0.5	9
1516	Cutaneous Involvement in Waldenström's Macroglobulinaemia. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00225.	0.6	7
1517	Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients with Cancer. <i>Current Oncology</i> , 2008, 15, 9-23.	0.9	29
1519	Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience. <i>Radiation Oncology Journal</i> , 2017, 35, 317-324.	0.7	2
1520	Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma. <i>Korean Journal of Internal Medicine</i> , 2010, 25, 301.	0.7	13
1521	Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 362.	0.7	12
1522	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 885-893.	0.7	9
1523	Prognostic Utility of Angiogenic Growth Factors; Basic FGF, VEGF and PDGF-bb in Patients with Lymphoma. <i>International Journal of Cancer Research</i> , 2014, 10, 96-105.	0.2	2
1524	Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 73-77.	0.3	1
1525	Advances in paediatric cancer treatment. <i>Translational Pediatrics</i> , 2014, 3, 156-82.	0.5	45
1526	Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, S248-S253.	0.3	11
1527	Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation. <i>Indian Journal of Cancer</i> , 2017, 54, 430.	0.2	9
1528	Prognostic Implication of Programmed Death-1-Positive Tumor-infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma. <i>Korean Journal of Pathology</i> , 2011, 45, 573.	1.2	2
1529	Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 919-932.	1.3	14
1530	Differences in Treatment Patterns and Health Care Costs among Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Patients Receiving Rituximab in the Hospital Outpatient Setting versus the Office/Clinic Setting. <i>Journal of Cancer Therapy</i> , 2014, 05, 208-216.	0.1	8
1531	Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland. <i>Swiss Medical Weekly</i> , 2013, 143, w13748.	0.8	10
1532	Synchronous Primary Low-grade Mucosa-associated Lymphoid Tissue Lymphoma of Colon and Stomach. <i>Intestinal Research</i> , 2013, 11, 204.	1.0	6
1533	RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2009, 153, 211-214.	0.2	6

#	ARTICLE	IF	CITATIONS
1534	Diffuse Large B-Cell Lymphoma. Archives of Pathology and Laboratory Medicine, 2008, 132, 118-124.	1.2	90
1535	Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1125-1134.	2.3	15
1536	Impact of Inadequate Doses of Rituximab in the Treatment of Diffuse Large B Cell Lymphoma in Malaysian Patients. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1703-1706.	0.5	2
1537	Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biology and Medicine, 2014, 11, 20-33.	1.4	109
1538	Primary Vaginal Non-Hodgkin Lymphoma. Cureus, 2018, 10, e3713.	0.2	2
1539	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy increases carotid intima-media thickness and plaque score with von Willebrand factor activity elevation in patients with malignant lymphoma. Journal of Chemotherapy, 2022, 34, 258-263.	0.7	2
1540	Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. British Journal of Haematology, 2022, 196, 589-598.	1.2	4
1541	Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. Leukemia and Lymphoma, 2022, 63, 326-334.	0.6	3
1543	Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma â€” a Single-center, Retrospective Study. Acta Medica (Hradec Kralove), 2007, 50, 113-118.	0.2	0
1544	4. è¡€æŒ²è...«ç~é~ãÿÿ. Japanese Journal of Clinical Pharmacology and Therapeutics, 2007, 38, 387-391.	0.1	0
1546	Diagnosis and Treatment of Non-epithelial Malignant Tumors in the Anal Region. Nihon Daicho Komonbyo Gakkai Zasshi, 2008, 61, 998-1003.	0.1	1
1547	Development of Vaccine Therapy for Pancreas Cancer. , 2008, , 683-704.		0
1548	New proposal for the treatment of poor prognosis young patients with advanced stage diffuse large B-cell lymphoma. Revista Brasileira De Hematologia E Hemoterapia, 0, 30, .	0.7	0
1549	Biological therapy of B and T cell lymphoproliferative disorders. , 2009, , 693-709.		0
1550	Head and Neck Sarcomas and Lymphomas. Medical Radiology, 2009, , 103-115.	0.0	1
1551	Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies. , 2009, , 321-363.		0
1553	Efficacy and Adverse Effects of Rituximab Combined with a TCOP Regimen in Patients with Untreated Diffuse Large B-cell Lymphoma and Follicular Lymphoma. The Showa University Journal of Medical Sciences, 2009, 21, 215-225.	0.1	0
1554	Immunotherapy of Cancer. , 2009, , 209-240.		1

#	ARTICLE	IF	CITATIONS
1555	Primary breast lymphoma. , 2009, , 357-366.		0
1556	A case of mediastinal malignant lymphoma with cystic shadow and acute inflammation. The Journal of the Japanese Association for Chest Surgery, 2009, 23, 195-198.	0.0	0
1557	Recent advances in the treatment of B-cell lymphoma. F1000 Medicine Reports, 2009, 1, .	2.9	0
1558	Biologic Therapies For Non-hodgkin Lymphoma And Hodgkin Disease. , 2009, , .		0
1559	Monoclonal Antibody Therapy for Hematologic Malignancies. , 2010, , 493-536.		0
1560	Ocular Adnexal Lymphoproliferative Disease. Essentials in Ophthalmology, 2010, , 1-19.	0.0	0
1561	The Emerging Era of Targeted Therapy in Childhood Acute Lymphoblastic Leukemia. , 2010, , 3-18.		0
1562	Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma. Radiology and Oncology, 2010, 44, 232-8.	0.6	4
1564	Localisation gastro-intestinale. , 2010, , 75-79.		0
1565	Active tumor targeting drug delivery system: the current status. Academic Journal of Second Military Medical University, 2010, 30, 321-328.	0.0	0
1567	Pneumocystis jiroveci Pneumonia in a Patient with Diffuse Large B-Cell Lymphoma. , 2011, , 781-785.		0
1569	Hepatic toxicity and prognosis in HCV-infected patients with diffuse large B-cell lymphoma in the rituximab era. Okayama Igakkai Zasshi, 2011, 123, 85-89.	0.0	0
1573	Immunophenotypical Switch versus Tumor Heterogeneity in a Patient with HIV-Associated Diffuse Large B-Cell Lymphoma. Pathology Research International, 2011, 2011, 1-5.	1.4	2
1575	Targeted Therapies in Hematological Malignancies. , 0, , .		0
1576	Kapitel E1 Literaturverzeichnis zu Peter, Pichler, MÃ¼ller-Ladner (Hrsg.): Klinische Immunologie. , 2012, , e1-e80.		0
1577	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
1578	Aggressive (hoch maligne) Non-Hodgkin-Lymphome. , 2012, , 447-471.		0
1579	Non-Hodgkinâ€™s Lymphomas. , 2012, , 115-157.		0

#	ARTICLE	IF	CITATIONS
1580	Successful Management of Adverse Events in a Case of Follicular Lymphoma Treated with Bendamustine as Outpatient Cancer Chemotherapy. Iryo Yakugaku (Japanese Journal of Pharmaceutical) Tj ETQq0 00rgBT /Overlock 10		0
1581	Non-Hodgkin's Lymphoma. , 2012, , 1545-1572.		0
1582	Lymphomas of the Testis in Elderly Patients. , 2013, , 323-334.		0
1583	Lymphoma Surveillance Counterpoint: Japan. , 2013, , 467-468.		0
1584	Prognostic Factors in HIV-Associated Lymphoma. , 2013, , 153-169.		0
1585	Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 73-92.	0.1	0
1586	Tumoren des lymphatischen Systems. , 2013, , 799-851.		0
1587	HÄmatologie und Onkologie. , 2013, , 217-267.		0
1588	Lymphome diffus Ä grandes cellules B. , 2013, , 65-81.		0
1589	Rare Primary Tumors of the Pancreas. Updates in Surgery Series, 2013, , 159-174.	0.0	1
1590	Diffuse Large B-Cell Lymphoma. , 2013, , 177-202.		0
1592	MicroRNAs in Hematologic Malignancies. , 2014, , 67-95.		0
1593	Non-hodgkinlymfoom. , 2014, , 147-158.		0
1594	Acknowledgments / The Authors. , 2013, , 295-295.		0
1595	Lymphoma, Non-Hodgkinâ€™sâ†. , 2014, , .		0
1596	Special Issues in Pregnancy. , 2014, , 914-925.e3.		0
1597	Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World Journal of Hematology, 2014, 3, 29.	0.1	0
1598	Hematopoietic Stem Cell Transplantation in Lymphomas: including our hospital experience. Journal of the Nihon University Medical Association, 2015, 74, 213-218.	0.0	0

#	ARTICLE	IF	CITATIONS
1599	Molecular Targeted Drugs and Tumors. World Journal of Cancer Research, 2015, 05, 65-73.	0.1	0
1600	A Case of Extranodal Non-Hodgkin's Lymphoma in which Otitis Media with Effusion and Combined Hearing Loss Developed as the Initial Symptoms. Practica Otologica, Supplement, 2015, 141, 18-19.	0.0	0
1601	Progress in Clinical Use of CC Chemokine Receptor 4 Antibody for Regulatory T Cell Suppression. , 2015, , 207-227.		1
1602	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
1603	Réanimation des patients d'onco-hématologie : nouvelles thérapeutiques, nouvelles complications, nouveaux contrats d'admission. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 293-312.	0.0	0
1604	A History of Diffuse Large B cell Lymphoma: Aiming for Better Outcomes and Higher Cure Rates. Hematology & Transfusion International Journal, 2015, 1, .	0.1	0
1605	Research advances in reactivation of hepatitis virus after chemotherapy for non-Hodgkin's lymphoma-combined hepatitis B virus infection. Infection International, 2015, 4, 75-80.	0.1	0
1607	Hématologie und Onkologie. , 2016, , 225-276.		0
1608	Treatment of B-cell lymphomas. , 2016, , 45-57.		0
1609	Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a Report from Iran. Asian Pacific Journal of Cancer Prevention, 2016, 17, 1513-1517.	0.5	2
1610	Diffuse Large B-Cell Lymphoma. , 2017, , 29-43.		0
1611	Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia. , 2017, , 201-237.		0
1612	Lymphoproliferative Disorders. , 2017, , 1-7.		0
1613	Diffuse large B-cell lymphoma. , 2017, , 139-153.		0
1614	Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes. Journal of Hematology (Brossard, Quebec), 2017, 6, 33-43.	0.4	5
1615	Aggressive (hoch maligne) Non-Hodgkin-Lymphome. , 2017, , 485-510.		0
1617	COMPARISON IMMUNOCHEMOTHERAPY AND CHEMOTHERAPY EFFICASY IN FOLLICULAR LYMPHOMA. , 2017, 16, 24-31.	0.3	0
1618	Loss of CD20 Expression in Follicular Lymphoma after Program Anti-Tumor Therapy Including Rituximab: Literature Data and Case Report. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2017, 10, 176-181.	0.1	0

#	ARTICLE	IF	CITATIONS
1619	A Vision of Acupuncture in Western Medicine. International Journal of Complementary & Alternative Medicine, 2017, 6, .	0.1	0
1620	Primary testicular lymphoma. Vnitri Lekarstvi, 2017, 63, 415-422.	0.1	1
1621	Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma. Anticancer Research, 2017, 37, 6839-6843.	0.5	7
1622	Intensified therapy in diffuse large B-cell lymphoma. Oncotarget, 2018, 9, 12548-12549.	0.8	0
1623	Diffuse Large B-Cell Lymphomas in Older Adults. , 2018, , 1-31.		0
1624	Leitsymptom. , 2018, , 67-100.		0
1625	Lymphoproliferative Disorders. , 2018, , 259-265.		0
1626	Diffuse large B-Cell lymphoma-review. Journal of Medical Sciences (Taiwan), 2018, 38, 137.	0.1	4
1627	Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era. Journal of Cancer Research and Therapeutics, 2018, 14, 1397-1402.	0.3	0
1628	Zastosowanie infuzyjnego schematu chemioterapii DA-EPOCH w leczeniu chłoniaków agresywnych. Acta Haematologica Polonica, 2018, 49, 85-91.	0.1	0
1629	Standard of Care Relapsed DLBCL. Technik Im Fokus, 2019, , 157-166.	0.2	0
1630	Standard of Care in First-Line Therapy of DLBCL. Technik Im Fokus, 2019, , 145-155.	0.2	0
1631	Five Cases of Primary Malignant Lymphoma of the Paranasal Sinus. Nihon Bika Gakkai Kaishi (Japanese) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.6	0
1632	HÄmatologie und Onkologie. , 2019, , 231-288.		0
1633	Resistance to Monoclonal Antibody Therapeutics in Lymphoma. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 27-55.	0.1	0
1634	Giving the Axe to R-CHOP?. , 2019, 16, .		0
1635	Stress induced premature senescence promotes proliferation by activating SENEX and p16INK4a/Retinoblastoma (Rb) pathway in Diffuse Large B-cell Lymphoma. Turkish Journal of Haematology, 2019, 36, 247-254.	0.2	2
1636	Renal involvement in diffuse large B-cell lymphoma: A case report. Marmara Medical Journal, 0, , .	0.2	0

#	ARTICLE	IF	CITATIONS
1637	Mature B-Cell Acute Lymphoblastic Leukemia. , 2020, , 73-80.		1
1639	Feasibility of up-front autologous stem cell transplantation for high risk diffuse large B-cell lymphoma – non-randomized analysis of 58 consecutive patients. Acta Haematologica Polonica, 2020, 51, 151-156.	0.1	0
1640	Therapy Response Imaging in Lymphoma and Hematologic Malignancies. Medical Radiology, 2020, , 177-200.	0.0	0
1641	Non-Hodgkin lymphoma. , 2020, , 5288-5302.		0
1642	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
1645	Age-Related Disease Risks in Younger versus Older B-Cell Non-Hodgkin's Lymphoma Survivors. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2268-2277.	1.1	2
1646	Hochmaligne Non-Hodgkin-Lymphome. , 0, , 385-420.		0
1647	Non-Hodgkin's Lymphoma. Medical Radiology, 2008, , 399-413.	0.0	3
1648	Lymph nodes and spleen. , 2015, , 688-812.		1
1649	Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P and T, 2010, 35, 148-57.	1.0	85
1650	NHL (diffuse large B cell lymphoma). Clinical Evidence, 2008, 2008, .	0.2	2
1651	NHL (diffuse large B-cell lymphoma). Clinical Evidence, 2010, 2010, .	0.2	2
1652	Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status. Cancer Biology and Medicine, 2013, 10, 1-9.	1.4	11
1653	Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 459-65.	0.7	9
1654	A Challenging Case of Primary Breast Hodgkin's Lymphoma. MÃ  dica, 2015, 10, 44-7.	0.4	3
1655	Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 516-23.	0.7	2
1656	Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. International Journal of Clinical and Experimental Medicine, 2015, 8, 14656-71.	1.3	32
1657	Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 15340-50.	1.3	5



#	ARTICLE	IF	CITATIONS
1658	Combination of celecoxib (Celebrex) and CD19 CAR-redirced CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas. American Journal of Clinical and Experimental Immunology, 2017, 6, 27-42.	0.2	2
1659	Consolidation radiotherapy for advanced-stage aggressive B-cell non-Hodgkin lymphoma: A systematic review and meta-analysis. EXCLI Journal, 2017, 16, 1233-1248.	0.5	2
1666	Appropriate management of molecular subtypes of diffuse large B-cell lymphoma. Oncology, 2014, 28, 326-34.	0.4	11
1667	Outcomes of Diffuse Large B-Cell Non-Hodgkin's Lymphoma After Gemcitabine-Based Second Salvage Chemotherapy: A Single-Center Study. Cureus, 2021, 13, e19699.	0.2	0
1668	Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions. Cancers, 2021, 13, 5827.	1.7	18
1669	Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1324-1326.	2.3	0
1670	HOXD3 Up-regulating KDM5C Promotes Malignant Progression of Diffuse Large B-Cell Lymphoma by Decreasing p53 Expression. , 2021, , .		3
1671	Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India. Frontiers in Oncology, 2021, 11, 770747.	1.3	3
1672	MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Therapeutic Advances in Hematology, 2022, 13, 204062072110728.	1.1	11
1673	Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma. Annals of Hematology, 2022, 101, 763.	0.8	1
1674	Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	3
1675	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. Blood Advances, 2022, 6, 2745-2756.	2.5	3
1676	Safety Profile of Monoclonal Antibody Compared With Traditional Anticancer Drugs: An Analysis of Henan Province Spontaneous Reporting System Database. Frontiers in Pharmacology, 2021, 12, 760013.	1.6	3
1677	KIR2DS1&#x2013;HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematology,the, 2022, 9, e133-e142.	2.2	5
1678	Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes. Leukemia and Lymphoma, 2022, 63, 1556-1565.	0.6	3
1679	Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, 2022, 40, 369-381.	0.8	60
1680	Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma. Advances in Hematology, 2022, 2022, 1-7.	0.6	7
1681	PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS. Frontiers in Oncology, 2022, 12, 824632.	1.3	3

#	ARTICLE	IF	CITATIONS
1682	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791.	1.7	2
1683	DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 698-709.	0.3	1
1684	Clinicopathologic features and outcomes of diffuse large B-cell lymphoma with extranodal involvement: A retrospective analysis. <i>Cancer Research Statistics and Treatment</i> , 2022, 5, 67.	0.1	0
1685	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Human Immunodeficiency Virus-Associated Lymphoma Administered Highly Active Antiretroviral Therapy: Central and Western China Aids Lymphoma League 001 Study (cw-CALL 001). <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1686	Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-cell lymphoma – results of a single center, retrospective cohort in China. <i>Hematological Oncology</i> , 2022, 40, 617-625.	0.8	6
1687	Screening for Prognostic microRNAs Associated with Treatment Failure in Diffuse Large B Cell Lymphoma. <i>Cancers</i> , 2022, 14, 1065.	1.7	4
1688	Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma. <i>Antibodies</i> , 2022, 11, 15.	1.2	3
1689	Evolution of therapy for limited stage diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 33.	2.8	9
1690	CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 837457.	2.2	9
1692	Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	0.6	1
1693	Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018. <i>Blood Cancer Journal</i> , 2022, 12, 38.	2.8	6
1694	DLBCL 1L – What to Expect beyond R-CHOP?. <i>Cancers</i> , 2022, 14, 1453.	1.7	7
1695	Risk Factors for Neutropenia after the First Cycle of Chemotherapy for Non-Hodgkin Lymphoma. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 73-77.	0.1	0
1696	Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 754964.	1.3	7
1697	Pretreatment frailty is an independent prognostic factor among elderly patients with B-cell lymphoma undergoing immunochemotherapy: A prospective observational cohort study in Taiwan. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	0
1698	Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial. <i>BMC Cancer</i> , 2022, 22, 403.	1.1	1
1699	Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e804-e814.	0.2	4
1700	Treatment approach to diffuse large B-cell lymphomas. , 0, , 286-307.		0

#	ARTICLE	IF	CITATIONS
1702	BSH 2020 Student Essay Prize â€”How are you inspired by haematology and how will you inspire others to become haematologists?â€™. <i>British Journal of Haematology</i> , 2020, 191, 636-639.	1.2	0
1703	Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second lineâ€”A populationâ€”based study of 736 patients. <i>British Journal of Haematology</i> , 2022, 198, 267-277.	1.2	16
1704	Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. <i>BMC Health Services Research</i> , 2022, 22, 553.	0.9	1
1706	R-mini CHP in â€”80-year-old Patients with Diffuse Large B-cell Lymphoma: A Multicenter, Open-label, Single-arm Phase II Trial Protocol. <i>Acta Medica Okayama</i> , 2018, 72, 315-318.	0.1	2
1707	Immunohistochemical expression of CD-10, BCL-6 and MUM-1 antibodies and immediate clinical response in patients of diffuse large B-cell lymphomas after six cycles of chemotherapy. <i>Journal of the College of Physicians and Surgeonsâ€”Pakistan: JCPSP</i> , 2014, 24, 722-7.	0.2	0
1717	Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma. <i>Leukemia Research Reports</i> , 2022, 17, 100319.	0.2	0
1718	A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020. <i>Computers in Biology and Medicine</i> , 2022, 146, 105565.	3.9	9
1719	All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
1720	Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments. <i>Critical Reviews in Oncology/Hematology</i> , 2022, , 103711.	2.0	1
1722	Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1723	The Nitrogen Mustards. <i>Pharmacological Reviews</i> , 2022, 74, 552-599.	7.1	13
1724	Less Intensive Regimens May Still Be Suitable for the Initial Treatment of Primary Mediastinal B-Cell Lymphoma in Resource-Limited Settings. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	2
1725	Risk of diabetes and the impact on preexisting diabetes in lymphoma patients treated with steroid-containing immunochemotherapy. <i>Blood Advances</i> , 0, , .	2.5	0
1726	Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2022, 14, 2932.	1.7	5
1727	Low lymphocyteâ€”toâ€”monocyte ratio predicts poor outcome in highâ€”risk aggressive large Bâ€”cell lymphoma. <i>EJHaem</i> , 2022, 3, 681-687.	0.4	1
1729	Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211033.	1.1	11
1730	Primary diffuse large B-cell lymphoma of the Larynx. <i>Auris Nasus Larynx</i> , 2022, , .	0.5	0
1731	PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas. <i>Biomedicines</i> , 2022, 10, 1587.	1.4	6

#	ARTICLE	IF	CITATIONS
1732	Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211104.	0.5	2
1733	Generalizability of landmark clinical trials in diffuse large B cell lymphoma to real-world patients: a single-center retrospective cohort study. <i>Leukemia and Lymphoma</i> , 0, , 1-4.	0.6	0
1734	Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission. <i>British Journal of Cancer</i> , 0, , .	2.9	1
1735	Post-chemotherapy pneumonia in Chinese patients with diffuse large B-cell lymphoma: Outcomes and predictive model. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1736	Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study <scp>MabScale</scp>. <i>Cancer Medicine</i> , 2023, 12, 2739-2751.	1.3	2
1737	The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e1051-e1058.e1.	0.2	3
1738	Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4642-4651.	3.3	18
1739	Clinical characteristics and outcomes of newly diagnosed patients with <scp>HIV</scp>-associated aggressive B-cell <scp>NHL</scp> in China. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 5067-5077.	1.6	7
1740	IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies. <i>European Journal of Immunology</i> , 2022, 52, 1648-1661.	1.6	2
1741	Primary diffuse large B-cell lymphoma of the right kidney: a case report. <i>Pan African Medical Journal</i> , 0, 42, .	0.3	1
1742	Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases. <i>DARU, Journal of Pharmaceutical Sciences</i> , 0, , .	0.9	1
1743	Apatinib enhances chemosensitivity of <scp>ABT</scp>-199 in diffuse large B-cell lymphoma. <i>Molecular Oncology</i> , 2022, 16, 3735-3753.	2.1	1
1744	Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies. <i>Biomolecules</i> , 2022, 12, 1261.	1.8	2
1745	IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study. <i>Leukemia</i> , 2022, 36, 2719-2723.	3.3	5
1746	Lymphomas in cartilage-hair hypoplasia – A case series of 16 patients reveals advanced stage DLBCL as the most common form. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1747	Construction of tandem diabody (IL-6/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	1
1748	Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP. <i>Expert Review of Hematology</i> , 2022, 15, 805-812.	1.0	1
1749	III. Diffuse Large B-cell Lymphoma. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 1404-1410.	0.0	0

#	ARTICLE	IF	CITATIONS
1751	Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 1577-1589.	0.8	12
1752	Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018). , 2023, 1, 3-11.		4
1754	Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
1756	Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [ <i>&lt;i&gt;Grupo de Estudio de Linfoproliferativos de Latino Am�rica&lt;/i&gt;</i> (GELL)]. <i>Hematology</i> , 2022, 27, 1208-1216.	0.7	1
1757	Search for Risk Factors Influencing the Occurrence of Infusion Reaction after Initial Treatment with Obinutuzumab. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2021, 47, 631-638.	0.0	2
1758	Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. <i>JCO Global Oncology</i> , 2022, , .	0.8	2
1759	Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 154-167.	1.3	3
1760	Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs. <i>Leukemia and Lymphoma</i> , 0, , 1-12.	0.6	1
1761	Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma. <i>Leukemia</i> , 0, , .	3.3	1
1762	Primary Mediastinal Large B-Cell Lymphoma. , 2017, , 343-353.		1
1763	A Protocol and Ethical Framework for the Distribution of Rationed Chemotherapy. <i>Journal of Clinical Ethics</i> , 2014, 25, 102-115.	0.1	11
1764	Deep learning-based classifier of diffuse large B-cell lymphoma cell-of-origin with clinical outcome. <i>Briefings in Functional Genomics</i> , 0, , .	1.3	0
1765	Role of estrogen receptor signaling pathway-related genes in diffuse large B-cell lymphoma and identification of key targets via integrated bioinformatics analysis and experimental validation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1766	Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1767	Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B-cell lymphoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1768	First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial. <i>HemaSphere</i> , 2022, 6, e808.	1.2	2
1769	Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 121-126.	1.1	1
1770	Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL. <i>Neurologia Medico-Chirurgica</i> , 2023, , .	1.0	0

#	ARTICLE	IF	CITATIONS
1771	Establishment and evaluation of a nomogram for predicting the survival outcomes of patients with diffuse large B-cell lymphoma based on International Prognostic Index scores and clinical indicators. <i>Annals of Translational Medicine</i> , 2023, 11, 71-71.	0.7	1

1772	Molecular classification and therapeutics in diffuse large B-cell lymphoma. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	0
------	--	-----	---

1773	Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults. <i>Best Practice and Research in Clinical Haematology</i> , 2023, 36, 101463.	0.7	1
------	---	-----	---

1774	Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults. <i>Best Practice and Research in Clinical Haematology</i> , 2023, 36, 101463.	0.7	1
------	---	-----	---

A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, 1775

#	ARTICLE	IF	CITATIONS
1816	Anti-CD20 antibody treatment for B-cell malignancies. , 2024, , 31-75.		0
1817	Clinical efficacy of anti-CD20 antibodies in autoimmune diseases. , 2024, , 273-298.		0